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Abstract 

Skin wound healing is a tightly regulated sequence of events involving activation and 
interplay of various cell types. Dermal fibroblasts guide crucial re-epithelialization events 
such as keratinocyte migration and proliferation. Fibroblast-keratinocyte interaction is 
directed by paracrine factors as well as cell-cell and cell-extracellular matrix contacts. In 
large-scale wounds, such as burns, the intrinsic capacity for healing is compromised due to 
lack of dermal support. 
 
Fibroblasts as well as other mesenchyme-derived cells such as bone marrow stromal 
cells can produce a vast array of growth factors in vitro. When activated by deprivation of 
extracellular matrix cell adhesion sites, the cells prefer cell-to-cell contacts, form clusters, and 
release growth factors. This present work focused on characterizing the use of a combination 
of growth factors released by mesenchymal cell aggregates, a process designated as nemosis, 
for treatment of skin wound healing. 
 
We used inhibitors of several intracellular signaling pathways to define the migration-
inducing mechanisms of nemosis using a keratinocyte wound-healing assay. Model human 
keratinocytes HaCaT-cells responded to the nemosis-derived conditioned medium with 
enhanced migration, proliferation, and viability. A c-Met-specific small molecule tyrosine 
kinase inhibitor as well as an anti-hepatocyte growth factor antibody inhibited these 
responses. The study aimed to characterize means of improving wound healing by combining 
biological materials, such as fibrin or recombinant human collagen III with the growth factors 
to construct a transplantable cell- and growth factor-containing matrix. The effect of these 
active matrices on wound healing was analyzed in porcine partial-thickness and full-thickness 
wound models.  
 
We observed that conditioned medium from cell aggregates could easily be trapped, 
transferred to the wound, and gradually released from a fibrin matrix. When we treated 
porcine partial-thickness wounds with the growth factor-containing fibrin matrix, we observed 
an increase in the proliferation and migration of hair-follicle and lateral wound-edge 
keratinocytes. In addition, granulation tissue formation was enhanced when compared with 
formation on saline-treated wounds. We found that keratinocyte transplantation in porcine full 
thickness wounds was feasible with a recombinant human collagen type III matrix. 
 
The results presented here indicate that cell-cell contact-activated fibroblasts or bone 
marrow stromal cells improve keratinocyte transplantation with paracrine factors. Fibrin or 
recombinant human collagen III can serve as vehicles for delivery of these signals to the 
target site in acute wounds. Since these factors are also crucial for healing of chronic non-
healing wounds, it is likely that our therapeutic approach will be of benefit in their treatment, 
too. 
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1. Introduction 
 
The skin is the largest organ of the human body. It maintains body homeostasis by 
regulating temperature and fluid balance, produces vitamin D, and provides an essential 
barrier that protects us from the environment. After injury to the skin, a complex series of 
tightly controlled responses are initiated to restore its integrity. In extensive tissue damage, as 
observed in burns or other large tissue defects, the regenerative capacity of skin is 
compromised, causing impaired and delayed healing. Thus, to replace lost tissue, skin 
transplantation from uninjured areas is necessary. Skin-graft harvesting, on the other hand, 
creates a new wound. When the skin is extensively burned, the surgeon is faced with a lack of 
healthy donor sites. The time-consuming epithelialization of both donor sites, as well as the 
interstices of largely meshed skin grafts, leaves the body without a proper barrier function 
rendering it susceptible to infection and dehydration, that critically contribute to both 
morbidity and mortality (Church et al., 2006). 
 
For a skin wound to heal, an adequate circulation of blood and nutrients is mandatory. 
Necrotic material and wound debris, a nutrient for bacteria, needs to be repeatedly removed. 
Additionally, wound moisture is critical, since surface dessication impairs healing, 
epithelialization in particular. As a conclusion, the wound microenviroment plays an essential 
role in healing. Systemic diseases can weaken the wound-healing response and clinicians 
frequently encounter hard-to-heal skin wounds. Most common are chronic non-healing 
wounds of the lower limb caused by diabetes or venous insufficiency, which heal slowly and 
require debridement and skin grafting (Briggs et al., 2004). These wounds are a major clinical 
problem; a substantial burden on healthcare costs. 
 
Although a wide variety of products for the treatment of wounds exist, with new ones 
constantly emerging, many are expensive, complicated to use, or inefficient. A need to 
develop novel means of treating wounds and understanding the mechanisms of wound healing 
therefore remains. Growth factors and cytokines are key components in wound healing, and 
because their amount and activity are reduced in non-healing wounds, targeted delivery of 
these essential mediators to the wound bed is considered promising in promoting healing and 
epithelialization (Lauer et al., 2000). One method to produce an array of growth factors in 
large quantities is the activation of dermal fibroblasts by cell-to-cell contacts when cultivated 
as cell aggregates (Furukawa et al., 2001; Bizik et al., 2004; Kankuri et al., 2005). Activation 
of cells by their cultivation on non-adherent surfaces such as cell clusters produces a 
biologically effective concentration of growth factors and cytokines (Bizik et al., 2004; 
Kankuri et al., 2005).  
 
In the present study, we characterized the effect of paracrine factors produced by 
aggregation-activated fibroblasts and bone marrow stromal cells on keratinocyte wound 
healing. Furthermore, we studied their transfer and effect in matrices on experimental porcine 
partial- and full thickness wounds. 
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2. Review of the literature 
2.1 Skin structure and function 
The skin consists of two distinct layers: the fibroblast-containing dermis and the 
keratinocyte-populated constantly renewing epidermis. The dermis, responsible for the skin’s 
strength and pliability, provides support and nutrition to the epidermis and contains sweat 
glands, hair follicles, and associated sebaceous glands (Figure 1A). The epidermis can be 
divided into several separate epithelial layers based on proliferation and differentiation states. 
The proliferating stem and transit-amplifying cells in the basal layer differentiate layer by 
layer, lose their nucleus during this differentiation process, and eventually become dead 
corneocytes of the outermost stratum corneum (Figure 1B). The skin provides the body with a 
barrier against the outer world; the barrier that protects us from the environmental threats, 
prevents water loss, and provides thermal homeostasis (Montagna, 1962). Loss of barrier 
integrity, as a result of injury or disease, may lead to significant disability or even death 
(Singer and Clark, 1999). 
 
 
 
Figure 1. A schematic presentation of skin anatomy and essential skin structures (A) and layers of the 
epidermis (B). Adapted from The Web site of the National Cancer Institute (http://www.cancer.gov) and 
wikimedia commons, Files: Skin layers.png, Skinlayers.png 
 
Recent studies indicate that there are multiple epidermal stem cell pools in distinct 
compartments (Watt and Jensen, 2009) (Figure 2). The hair follicle bulge reservoir is crucial 
for the maintainance of basal unipotent epidermal cells in the interfollicular epidermis. In 
uninjured skin, stem cells divide slowly. In respose to injury, however, they activate and 
rapidly proliferate supplying cells needed for epithelialization. In superficial wounds, 
restoration of the epidermal barrier can occur through proliferation and migration of 
 
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epidermal stem cells in the basal cell layer (Figure 1B and 2). Wounds extending to the dermis 
are first replaced by granulation tissue that provides survival time and a supporting structure 
for stem cells in the hair follicle, and in sebaceous and sweat glands (Figure 2) to activate, 
migrate, and proliferate (Martin, 1997). If the wound extends below the dermis, the skin can 
heal only through scarring and contraction (Singer and Clark, 1999). 
 
Figure 2. Skin stem cells. Epidermal stem cell (1), sebaceous stem cell (2), hair follicle bulge stem 
cell (3), sweat gland stem cell (4), melanocyte stem cell (5), connective tissue sheet mesenchymal 
stem cell (6), neural stem cell (7), and endothelial stem cell (8). 
From Brouard and Barrandon, Current Opinions in Biotechnology 2003,15,520-252.  Used with the 
permission of the copyright holder.  
2.2 Skin wounds and wound healing  
The skin is continuously exposed to the environment and is subject to mechanical 
stress, injury, and ultraviolet-radiation. Its well-being therefore depends on a tightly regulated 
healing process: a complex sequence of events in which every step is crucial for restoration of 
tissue integrity and function (Martin, 1997). Wound healing is a precisely orchestrated 
interplay between different cell types involving several mediators (Figure 3, Table I) and a
multitude of intracellular signaling pathways (Singer and Clark, 1999). Immune cells 
(neutrophils, monocytes, lymphocytes, and dendritic cells), endothelial cells, keratinocytes, 
and fibroblasts undergo changes in gene expression and phenotype resulting in cell 
proliferation, differentiation, and migration (Schafer and Werner, 2007; Gurtner et al., 2008). 
Classically, three overlapping phases of wound healing can be characterized: inflammation, 
synthesis, and remodelling. 
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2.3 Stages of wound repair 
2.3.1 Inflammation 

The role of the acute inflammatory phase is to stop the loss of fluid and blood, to 
remove devitalized tissue, and to counteract infection (Gurtner et al., 2008). Immediately after 
injury, platelet aggregation initiates hemostasis, which is followed by the assembly of a fibrin 
matrix, which becomes the scaffold for migrating cells (Postlethwaite et al., 1981; Clark et al., 
1982). In skin-wound healing, infiltrating leukocytes are the first-line cellular components of 
the inflammatory response (Eming et al., 2007). Interleukin-1 (IL-1), released by damaged 
keratinocytes after epidermal injury, acts as the first signal to alert surrounding and circulating 
cells (Kupper et al., 1986; Freedberg et al., 2001), (Figure 3). Neutrophils are also recruited to 
the wound by bacterial degradation products, activation of complement, degranulation of 
platelets, and the release of platelet-derived growth factor (PDGF) (Grose et al, 2004).  
 
After infiltration, neutrophils produce a wide variety of inflammatory cytokines, such 
as tumor necrosis factor alpha (TNF-α), IL-1 and IL-6, which in turn modulate the 
inflammation response by promoting cytokine production and leukocyte migration 
(Szpaderska et al., 2003). After 2 to 3 days, monocytes migrate to the wound and differentiate 
into macrophages. The importance of macrophages in the process of wound healing is not yet 
totally understood. Macrophages support wound repair by serving as antigen-presenting cells 
and phagocytes (Gordon et al., 2003). Macrophages also synthesize numerous potent growth 
factors, such as transforming growth factor beta (TGF-β), TGF-α, basic fibroblast growth 
factor (bFGF, also known as FGF2), PDGF, and vascular endothelial growth factor (VEGF), 
that support cell proliferation and synthesis of extracellular matrix (ECM) (Brancato and 
Albina, 2011) (Figure 3). On the other hand, macrophage deficiency can be compensated for 
by the redundancy of the inflammatory response (Martin et al., 2005; Gurtner et al., 2008). 
Interestingly, it seems that the versatile macrophages are responsible both for the induction of 
fibrosis and for its clearance and resolution (Martin et al., 2005). 
 
2.3.2 Phase of synthesis  
 
Granulation tissue formation begins 2 to 10 days after injury and overlaps with the 
inflammatory phase. Fibroblasts and macrophages replace the fibrin matrix with a new ECM 
containing collagens I and III, glycosaminoglycans (GAG), and proteoglycans (Lawrence, 
1998). A number of growth factors, including PDGF, TGF-β, epidermal growth factor (EGF), 
(insulin-like growth factor) IGF-1, and FGF2 stimulate fibroblasts (Figure 3) (Werner and 
Grose, 2003; Vogler et al., 2003). PDGF functions as a chemoattractant for fibroblasts and 
stimulates collagen production. TGF-β promotes synthesis of collagen, fibronectin, hyaluronic 
acid, and other proteins in a variety of cell lines, reducing the proteolytic degradation of ECM 
components by reducing synthesis of protease inhibitors (Roberts et al., 1990); proteases are 
generally thought to activate various effects in cells. In unwounded skin and mature scars, 80 
14 
to 90% of the dermal collagen is type I, and type III collagen constitutes the remaining 10 to 
20%. In early wound healing, the amount of type III collagen is increased about three-fold 
(Monaco and Lawrence, 2003).  The phase of synthesis continues until the defect is filled with 
collagen that ultimately foms the bulk of the mature scar (Werner et al., 2007). 
  
Local changes in the tissue environment (increased lactate, decreased pH, and low 
oxygen) activate angiogenesis, which is a central feature of granulation tissue (Remensnyder 
and Majno, 1968; Li et al., 2003). Matrix metalloproteinases (MMPs) degrade the ECM and 
thus play a central role in activating angiogenesis, leukocyte infiltration and re-
epithelialization. Numerous growth factors activate angiogenesis, such as vascular endothelial 
growth factor A (VEGFA) and FGF2, angiopoietin, and TGF-β. During wound healing 
keratinocytes at the wound edge begin producing MMPs as they detach from the basement 
membrane and migrate across the wound bed on the newly formed provisional matrix (Clark 
et al., 1982; Raja et al., 2007; Schultz and Wysocki, 2009). Keratinocyte migration is 
stimulated by, for example, neuregulin (NRG), hepatocyte growth factor (HGF), and EGF 
(Werner and Grose, 2003). Keratinocyte proliferation is stimulated by factors such as: heparin 
binding-EGF (HB-EGF), HGF, IL-6, and granulocyte macrophage-colony stimulating factor 
(GM-CSF) (Werner and Grose, 2003).  
 
 
 
Figure 3. Paracrine stimulatory mediators and fibroblast-keratinocyte interactions in wound healing.  
ECM, extracellular matrix, bFGF, basic fibroblast growth factor, GM-CSF, granulocyte macrophage-
colony stimulating factor, HGF, hepatocyte growth factor, IL-1, interleukin 1, IL-6, interleukin 6, KGF, 
keratinocyte growth factor, PDGF, platelet-derived growth factor, TGF-β, transforming growth factor 
beta, TNF-α, tumor necrosis factor α. Arrows indicate stimulatory effects.  
Figure modified from Baum and Arpey, Dermatol Surg. 2005;31:674-86 with the permission of the 
copyright holder.  
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2.3.3 Remodeling 
 
The next stage of skin wound repair, remodeling, begins 2 to 3 weeks after injury and requires 
a year or more (Gurtner et al., 2008). During this stage, all the activated processes are 
gradually quenched. The majority of endothelial cells, macrophages, and fibroblasts undergo 
apoptosis (Kane and Greenhalgh, 2000) and the marked hypervascularity seen in granulation 
tissue disappears. The ECM is actively remodeled from mainly type III collagen-containing 
architecture into one composed of type I collagen (Lovvorn et al., 1999). The remodeling 
process is mainly executed by MMPs secreted by fibroblasts, macrophages, and endothelial 
cells (Lawrence, 1998). Although in some eukaryotic organisms the response to injury can 
completely regenerate the original tissue architecture; in mammals the skin never regains its 
uninjured properties (Levenson, 1965). 
 
 
2.4 Epidermal stem cells and wound healing 
 
In the injured skin, epidermal stem cells must also activate to provide efficient re-
epithelialization (Lavker and Sun, 2000). Present knowledge underlines the fact that multiple 
sources of these cutaneous stem cells exist (Figure 2), and that the unipotent stem cell in the 
basal layer of the epidermis is a progeny of the multipotent stem cell (Taylor et al., 2000; 
Brouard and Barrandon, 2003; Ito et al., 2005). However, with the lack of an absolutely 
specific single molecular marker, the characterization of epidermal stem cells is complicated. 
Multipotent epidermal stem cells identified experimentally as ‘‘label-retaining cells’’ staining 
positive for keratin 15, cluster of differentiation 34 (CD34) and leucine-rich repeat-containing 
G-protein-coupled receptor 5 (Lgr5), have been characterized in a specialized location within 
the outer root sheath of the hair follicle known as the bulge (Figure 2) (Roh and Lyle, 2006). 
Lgr5 is a downstream mediator of the wingless and int-pathway (WNT)-signaling pathway, 
found to be a marker for quiescent stem cell-like cells (Haegebarth and Clevers, 2009). 
Multipotent epidermal stem cells contribute to healing by migrating and producing transit-
amplifying cells that can undergo several divisions (Ito et al., 2005). A subpopulation of cells 
lacking the bulge marker CD34 lie just below the opening of the sebaceous gland and exhibit 
similar properties of multipotent keratinocyte stem cells (Jensen et al., 2008). The 
transcription factor c-myc is a regulator of epidermal stem cell fate (Watt, 1998). c-Myc 
knock-out mice exhibit delayed re-epithelialization because of the inability of interfollicular 
epidermal cells to produce daughter keratinocytes (Schafer and Werner, 2007) stating the 
importance of multipotent stem cells in healing (Figure 4). 
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2.5 Fibroblast populations and wound healing 
 
Paracrine signals from the underlying dermis control keratinocyte stem cell activity  
(Taylor et al., 2000) fibroblasts are considered a central player in the production of the 
dermis-derived paracrine stimuli (Werner et al., 2007). Different pools of dermal fibroblasts 
are defined according to their anatomical location as papillary, reticular and hair follicle-
associated dermal fibroblasts (review by Sorrell and Caplan, 2004) (Figure 1) and have various 
phenotypes (Harper and Grove, 1979; Azzarone and Macieira-Coelho, 1982). The hair 
follicle-associated dermal fibroblasts reside in the connective tissue sheet (CTS) of the hair 
follicle (Figure 2) (Jahoda and Reynolds, 1996). The present understanding is that local dermal 
fibroblasts arise from multipotent dermal mesenchymal stem cells of the CTS (Jahoda et al., 
2003). These stem cells display high telomerase activity and proliferative potential 
(Hoogduijn et al, 2006), and posses characteristic features of mesenchymal stem cells with the 
capacity to differentiate into adipocytes, chondrocytes, osteoclasts, functional smooth muscle 
cells, and keratinocytes in vitro (Crigler et al., 2007). In a healing wound, fibroblasts 
transform into contractile α-smooth muscle actin (SMA)-expressing myofibroblasts (Tomasek 
et al., 2002; Hinz et al., 2007). Myofibroblast differentiation and wound contraction are 
promoted by TGF-β (Vaughan et al., 2000) (Figure 3). Apart from TGF-β signals, mechanical 
tension, FGF2 and PDGF regulate fibroblast to myofibroblast phenotype switching (Tomasek 
et al., 2002; Werner and Grose, 2003). 
 
Figure 4. Location of hair 
follicle bulge epidermal stem 
cells and their migration and 
contribution of epithelialization 
in wound healing.  
 
From Turksen Dev Cell. 
2004;6:454-6. Used with the 
permission of the copyright 
holder. 

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2.5.1 Infiltrating mesenchymal cells 
 
 Knowledge of peripheral blood-derived fibroblasts participation in wound healing 
dates back almost 100 years (Dunphy, 1963). Bucala et al. (1994) described a distinct 
population of blood-borne fibroblast-like cells, termed “fibrocytes”, that rapidly infiltrated the 
location of tissue injury in a wound-chamber model. Later on, what became clear is that a 
distinct population of blood-derived CD34+/Col I+ fibroblast-like cells contribute to wound 
healing by secreting the chemokines, cytokines and growth factors involved in wound repair 
(Mori et al., 2005; Grieb et al., 2011). Additionally, the circulating peripheral blood is 
considered a significant source of bone marrow mesenchymal stem cells needed for skin 
repair and regeneration (Stramer et al., 2007). Opalenik and Davidson showed that bone 
marrow stromal cells contribute to granulation tissue formation by acquiring a fibroblast 
phenotype (Opalenik and Davidson, 2005). Bone marrow-derived stem cells also support 
epidermal regeneration through paracrine stimulus (Krause et al., 2001; Aoki et al., 2004). 
 
2.6 Paracrine interaction between dermal fibroblasts and keratinocytes 
 
The reactions and responses of the dermis during wound healing have received 
extensive attention. The first report in 1961 by McLoughlin was that mesenchymal factors 
were required for proper epidermal differentiation. Several other key observations followed 
(McLoughlin, 1961, Wessels 1964; Melbye et al., 1973), culminating with the method to 
successfully cultivate normal human keratinocytes using fibroblast feeder cells (Rheinwald 
and Green, 1975, 1977). The feeder cell co-culture system revealed clearly that epidermal cell 
phenotype depends on interaction with mesenchymal cells. Keratinocytes seeded on the 
feeder cell layers retained their proliferating non-differentiated state for a longer period of 
time (Rheinwald and Green, 1975 and 1977). After skin wounding, dermis-derived growth 
factors cause changes in gene expression and activate keratinocytes to acquire a proliferative 
and migratory phenotype (Schafer and Werner, 2007, Werner et al., 2007). Smola et al (1993) 
characterized that fibroblast-keratinocyte co-cultures produce increased levels of keratinocyte 
growth factor (KGF or FGF7), IL-6, and GM-CSF. It was also clear that IL-1 stimulus 
enhanced fibroblast KGF production at both the protein and mRNA level (Brauchle et al., 
1994; Chedid et al., 1994; Maas-Szabowski and Fusenig, 1996). KGF, in turn, promoted 
increased production of IL-1α from keratinocytes, suggesting a paracrine loop (Maas-
Szabowski et al., 1999) (Figure 3). 
 
2.6.1 Epidermal growth factor family 
 
The epidermal growth factor (EGF) family consists of EGF, TGF-α, HB-EGF, 
amphiregulin, betacellulin, epiregulin, and neuregulin (NRG-1, NRG-2, NRG-3, and NRG-4) 
(Harris et al., 2003). Various enzymes cleave the membrane-anchored precursor molecules of 
EGF-family growth factors to release their active soluble forms that then act in either a 
paracine or an autocrine manner. Upon binding to their receptor, the ErbB-receptor (also 
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generally referred to as EGFR), an intracellular signaling cascade is activated. The ErbB-
family is comprised of four receptors (ErbB 1-4) based on ligand affinity. EGF, TGF-α, and 
amphiregulin bind to ErbB1. HB-EGF, betacellulin and epiregulin bind to ErbB1 and ErbB4 
(Harris et al, 2003). Neuregulins binds to ErbB2-4 receptors, which are important for the 
development of cardiac muscle and the central nervous system (Shirakata, 2010). Human 
epidermal keratinocytes express ErbB1, ErbB2, and ErbB3, but not ErbB4 (Miettinen et al., 
1995; Hashimoto, 2000). In general, all EGF-family growth factors promote keratinocyte 
proliferation some extent. In wound healing, however, amphiregulin and EGF are considered 
the most potent mitogens for keratinocytes (McCawley et al., 1998; Hudson and McCawley, 
1998; Schelfhout et al., 2002). 
 
TGF-α, originally identified for its ability to induce a reversible phenotype 
transformation in fibroblast-like cells, is secreted by keratinocytes and promotes epithelial cell 
proliferation in an autocrine manner (Coffey et al., 1987). Like amphiregulin, TGF-α is over-
expressed in psoriasis (Elder et al., 1989). HB-EGF was first identified in the conditioned 
medium of macrophages. HB-EGF binds to two receptors, ErbB1 and ErbB4, and has high 
affinity for heparin (Higashiyama et al., 1991). Betacellulin is expressed by suprabasal 
keratinocytes in particular in the granular cell layer, stimulating keratinocyte growth and 
controling hair follicle development (Schneider et al., 2008). Several knock-out mouse 
models allow characterization of the specific functions of EGF-family members as well as 
ErbB1. Of particular interest, are the Waved-1 mice, which have a spontaneous mutation in 
the Tgfa gene and are hence TGF-α-deficient. They are characterized by unmistakable 
waviness of their hair and whiskers and display delayed healing of partial- but not full-
thickness wounds (Luetteke et al., 1993).  
 
2.6.2 Hepatocyte growth factor (HGF) 
 
Initially identified by its growth-promoting activities in hepatocytes and scattering-
inducing property in epithelial cells (Gherardi et al., 1989), HGF has since proven to be a 
multipotent growth factor with properties promoting angiogenesis, mitosis, cell migration and 
morphogenesis, and inhibiting apoptosis (Stella and Comoglio, 1999). Cellular responses to 
HGF are mediated by a specific receptor tyrosine kinase, c-Met, and by its 
autophosphorylation upon ligand binding (Ma et al., 2005). HGF binding to c-Met causes 
receptor dimerization and transient autophosphorylation of two tyrosine residues (Y1234 and 
Y1235) in the receptor’s intracellular b-chain (Ponzetto, 1994) (Figure 5). Mainly 
mesenchymal cells secrete HGF, which acts locally to stimulate epithelial cell and endothelial 
cell proliferation, and angiogenesis.  
 
HGF and c-Met have been explicitly linked to skin wound healing and hair follicle 
morphogenesis (Lindner et al., 2000). Interestingly, c-Met is upregulated in migrating 
keratinocytes with MMP-9 (McCawley et al., 1998; Chmielowiec et al., 2007), and deletion 
of the met-gene strongly delays epithelialization, a finding further supporting the essential role 
of HGF/c-Met signaling in re-epithelialization (Chmielowiec et al., 2007). The HGF amount 
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in both acute and chronic wounds is increased, whereas in the latter the activation of HGF 
most probably is inhibited due to an increased amount of HGF-inhibitors HAI-1 and HAI-2 
(Conway et al., 2007; Shirakata et al., 2007). 
 
2.6.3 Fibroblast growth factor family 
 
Thus far, 22 FGF members exist, and the high-affinity FGF receptor (FGFR) family 
consists of receptors FGFR 1 to 4. These tyrosine kinase receptors are transmembrane 
proteins, which work much like EGFR. KGF was one of the first growth factors involved in 
mesenchymal-epithelial interactions (Finch et al., 1989). It is rapidly induced in fibroblasts 
after wounding, exerts its paracrine effect through binding to its receptor FGFR2IIIb on 
keratinocytes, and promotes migration and proliferation (Brauchle et al., 1994; Chedid et al., 
1994). Upon injury, KGF expression is as much as to 100-fold upregulated by factors such as 
IL-1, TNF-α, and PDGF in mesenchymal cells. A similar upregulation is also linked to re-
epithelialization of split thickness wounds (Marchese et al., 1995). FGF2 increases in the 
acute wound, and plays a role in granulation tissue formation, re-epithelialization, and tissue 
remodeling (Powers et al., 2000). FGF2 plays a role in regulating the synthesis and deposition 
of various ECM components such as collagen by fibroblasts. It also increases keratinocyte 
motility during re-epithelialization (Sogabe et al., 2006).
Figure 5. The main intracellular kinase 
cascades activated after binding of 
HGF to its ligand-specific c-Met 
receptor and subsequent receptor 
homodimerization. Y1234 and Y1235, 
tyrosine residues of c-Met  
PI3K, phosphatidylinositol 3-kinase; 
MEK 1/2, MEK 3/6, mitogen activated 
protein kinase kinase; ERK1/2, 
extracellular signal-regulated kinase; 
p38, protein 38 activated MAP kinase.  
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2.6.4 Transforming growth factor β (TGFβ)  
 
In wound healing TGFβ exerts a broad range of biological effects, such as keratinocyte 
growth inhibition, production of extracellular matrix, and synthesis of plasminogen activator 
and its inhibitor (Sellheyer et al., 1993). In acute wounds, it binds to a heteromeric receptor 
complex consisting of a combined type I and type II receptor in fibroblasts, stimulating the 
production of collagen (Werner and Grose, 2003). Additionally, a non-signaling type III 
receptor exists, which has the function of presenting TGF-β to the type II receptor (Liu et al., 
2005). After autophosphorylation of serine-threonine kinases, the receptors activate 
downstream signaling molecules belonging to the Smad-family of transcription factors (Liu et 
al., 2005). 
 
2.6.5 Platelet-derived growth factor (PDGF) 
 
The PDGF family consists of growth factors including PDGF-AA, PDGF-AB, PDGF-
BB, PDGF-CC, and PDGF-DD. In addition to platelets, the macrophages, endothelial cells 
and keratinocytes produce PDGFs (Bennet et al., 2003). PDGFs bind to two separate 
transmembrane tyrosine kinase-receptors (α and β). Upon ligand binding and 
autophosphorylation, these receptors submit intracellular signaling through Src homology 2 
(SH2) domain-containing signaling molecules (Lederle et al., 2006). PDGFs exert various 
actions on fibroblasts and are considered predominantly keratinocyte-derived growth factors 
acting in a paracrine manner on fibroblasts supporting their proliferation and ECM-production 
(Werner et al., 2007). Additionally, the PDGF-BB isoform is able to induce KGF in 
mesenchymal cells and, thus affect keratinocyte migration and proliferation (Brauchle et al., 
1994). 
 
2.6.6 Interleukin 1, interleukin 6, and interleukin 8 
 
Inteleukins are polypeptides produced by activated cells during of inflammatory 
processes and have multiple targets and functions. Inflammation, trauma, and infection, 
among others, trigger a rapid release of pro-inflammatory cytokines IL-1, IL-6, TNFα and IL-
8. Interleukins are the central effector controlling production of acute-phase proteins and 
participate in alerting the body to acute changes (Gabay and Kushner, 1999). IL-1 is released 
immediately by keratinocytes in response to barrier injury and is produced as well by 
neutrophils, monocytes, and macrophages. It functions in both a paracrine and in an autocrine 
manner to cause increased keratinocyte migration and proliferation (Raja et al., 2007). In 
addition, IL-1 participates in mesenchymal-epithelial interaction (Figure 3) by activating 
fibroblasts to produce increased amounts of KGF (Tang and Gilchrest, 1996). IL-6 is a key 
cytokine in the initial steps of the wound-healing response. It is produced by neutrophils and 
macrophages, and has both pro- and anti-inflammatory properties. IL-6 has a mitogenic and 
proliferative effect on keratinocytes and its expression increases significantly after wounding. 
Interestingly, IL-6-knock-out mice display significantly delayed healing (Gallucci et al., 
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2004). Another prominent cytokine controlling keratinocyte responses is IL-8. Its primary role 
is to induce chemotaxis of neutrophils, but it also promotes migration and proliferation of 
keratinocytes (Schröder, 1992; Tuschil et al., 1992). 
 
 
 
 
 
 
"
 
Table I Summary of central factors promoting keratinocyte functions in wound healing  
  
Growth factors Cells Receptor in keratinocytes
EGF-family Fibroblasts ErbB1
Platelets (EGF, TGF-α, amphiregulin  
Macrophages HB-EGF, betacellulin and epiregulin
Keratinocyte (autocrine)
ErbB1
(neuregulin)
Hepatocyte growth factor (HGF) Fibroblasts c-Met
Keratinocyte growth factor (KGF) Fibroblasts FGFR2IIIb
Fibroblast growth factor 2 Keratinocytes FGFR2IIIb
Mast Cells
Fibroblasts
Endothelial cells
Smooth muscle cells
Transforming growth factor β Keratinocytes TGF-beta receptor I and II
 Macrophages
Lymphocytes
Fibroblasts
Platelet-derived growth factor (PDGF) Platelets PDGF receptor
Keratinocytes α and β
Macrophages
Endothelial cells
Interleukin 1, 6, 8 (IL-1, -6 and -8) Neutrophils, monocytes Interleukin receptor
macrophages
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2.7 Phosphoinositide-3-kinase (PI3K) signaling 
 
Various growth factor receptors, such as EFGR, c-Met and PDGF receptor, belong to a 
group of tyrosine kinase receptors. Binding of the ligand to its specific receptor triggers 
autophosphorylation of the tyrosine kinase enzyme, which activates various intracellular 
downstream cascades. One of these pathways, the phosphoinositide-3-kinase (PI3K), is 
closely associated with wound healing. It initiates signaling leading to keratinocyte 
proliferation and migration, and also contributes to epidermal homeostasis (Pankow et al., 
2006). In addition, PI3K-signaling is also involved in processes related to cell death and 
survival, and to intracellular vesicular transport (Vanhaesebroeck et al., 2012). An inhibitor of 
PI3K, LY294002 and its structural inactive analogue LY303511, have been useful in 
characterizing the effects of PI3K signaling (Arcaro and Wymann 1993; Vlahos et al., 1994). 
 
Tyrosine kinase receptors activate intracellular programs through PI3K, such as the 
signaling cascade that leads to activation of the mitogen-activated protein kinases (MAPKs) 
(Figure 5). This cascade involves at least three levels of hierarchically organized kinases. One 
level of MAPKs consists for example of extracellular signal-regulated kinases (ERKs) 1 and 2 
(ERK1/2); c-Jun amino-terminal kinases (JNKs) 1, 2, and 3; p38 isoforms α, β, γ and δ, ERKs 
3 and 4; and ERK5. A broad array of stimuli can activate MAPKs, but in general, ERK1 and 
ERK2 are preferentially activated in response to growth factors, while the JNK and p38 
kinases are more responsive to stress stimuli ranging from osmotic shock and ionizing 
radiation to cytokine stimulation (Pearson et al., 2001). ERK1/2 signaling has been associated 
with cell proliferation. There occurs considerable divergence and cross-talk between pathways 
on multiple levels. Two structurally independent compounds, U0126 (inhibits both mitogen-
activated protein kinase kinase 1 and 2: MEK1/2) and PD98059 (inhibits MEK 1) can serve to 
inhibit this cascade one level before MAPK (Ballif and Blenis, 2001). One of the prototype 
members of the MAPK-related pathway in mammalian cells is p38, which environmental 
stress and inflammatory cytokines activate. SB203580 is a typical p38 inhibitor, which has 
been very useful in describing the function of p38 in various experimental settings (Lee et al., 
1994) (Figure 5). 
 
2.8 Non-healing wounds 
2.8.1 Chronic ulcers  
 
By definition, chronic skin wounds fail to proceed through the orderly healing process 
over a period of 3 months according to Mustoe et al (2006) who defined four mechanisms in 
the pathogenesis of chronic wounds: local tissue hypoxia, repetitive ischemia-reperfusion 
injury, bacterial colonization of the wound, and altered cell and systemic response. 
Classically, three main factors account for the majority of patient cases: venous insufficiency, 
peripheral artery disease, and diabetes (Singer and Clark, 1999). Estimates are that in Finland 
20% of men and 40% of women suffer from venous insufficiency (Laurikka et al., 1993) and 
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it is present in up to 75% of cases with chronic wounds. Peripheral artery disease is present in 
up to 22% and diabetes in 25% of such cases (Graham et al., 2003; Briggs et al., 2004). 
Lymphodema is becoming an even more common factor behind impaired wound healing. 
Damage of the lymph system, caused by surgical removal of lymph nodes or radiation 
therapy, impairs lymph drainage and creates massive swelling in the affected limb. This 
subsequently decreases skin perfusion and results in breakdown and infection (Kershner et al., 
2008). Moreover, postinfectious damage of the lymph circulation can result from recurrent 
streptococcal erysipelas infections. Treatment of lymphodema and wounds caused by it is 
challenging. However, novel methods of gene therapy-induced lymphangiogenesis are 
promising (Cook, 2012).  
 
In addition, conditions such as vasculitis, malignancy, and connective tissue disorders 
may lead to development of a chronic wound. Pressure ulcers are heterogenous chronic-
wounds caused by is constant pressure of the skin causing local tissue hypoxia (Phillips, 
1994). Commonly a patient has more than one etiological factor causing the wound (Phillips, 
1994). 
 
In the western world, the prevalence of chronic wounds ranges between 0.04 and 1.1% 
(Graham et al., 2003; Moffatt et al., 2004). It is estimated that prevalence of active venous 
ulcers, the largest group of wounds, in the general population of older than 18 year olds is 
0.3%; incidence rate increases multiple times in the elderly population and is more common 
among females (Nicolaides, 2000; Laurikka et al, 1993). As chronic wounds commonly heal 
extremely slowly, within months or even years, they require multiple treatments and regular 
monitoring. Futhermore, once healed, chronic wounds frequently reappear. Based on multiple 
studies, it was concluded by the Royal Society of Medicine and Societas Phlebologica 
Scandinavica (1999) that the risk of recurrence of a venous ulcer is about 3-15%. Based on 
the figures presented by the wound society of Finland (Finnish Wound Treatment Society, 
2008) the estimate is that in Finland each year the cost toward treatment of chronic ulcers is 
190 to 270 million euros. The annual sum spent on drugs and other medical treatments per 
year is 2.2 billion euros, so treatment of chronic wounds is a noticeable in the total annual 
health care budget (Hjerppe et al., 2006; Health Expenditure and Financing 2009). 
 
Pathogenesis of chronic wounds 
Chronic wounds fail to proceed through the normal phases of wound healing, and 
remain in a chronic inflammatory state (Loots et al., 1998). Chronic disease, such as diabetes 
or venous insufficiency, disturb the normal inflammatory phase of wound healing, and causes 
inflammatory cells to produce proinflammatory cytokines in abundance. Futhermore, in 
venous insufficiency, the stasis causes pressure in the microcirculation, which exacerbates 
inflammatory processes; leukocyte migration into the interstitium increases, and cytokine and 
growth factor production enhances even more. The influx of neutrophils and macrophages is 
further aggravated by bacterial colonization, tissue hypoxia and decomposition. This exhausts 
the tissues intrinsic protective mechanisms and compromises healing (Palolahti et al., 1993; 
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Saarialho-Kere et al., 1998). The increased activity of MMP-2 and MMP-8 degrades growth 
factors and structural ECM proteins crucial for wound healing. In chronic venous stasis 
ulcers, the expression and activity of various MMPs, including collagenases (MMP-1, MMP-
8), gelatinases (MMP-2, MMP-9), stromelysins (MMP-3, MMP-10, and MMP-11), and the 
membrane type MMP (MT1-MMP) are upregulated (Saarialho-Kere, 1998; Gill and Parks, 
2008). These observations support the idea of treating chronic wounds by replacing damaged 
ECM components and growth factors (Eming et al, 2002; Schultz et al, 2009). 
 
2.8.2 Burns 

Data from two federal surveys in the United States, National Hospital Ambulatory 
Medical Care Survey (NHAMCS) and National Ambulatory Medical Care Survey (NAMC), 
show that approximately 450,000 burn injuries each year receive medical treatment including 
45,000 hospitalizations for burn injury (American Burn Association, 2011). In Finland, 900 
patients per year require hospitalization, of whom 10% are treated in intensive care units 
(personal information, Dr. J.Vuola). Burns heal slowly and require several wound treatments 
and multiple reconstructive operations to cover tissue defects as well as post-burn scar 
contractures. 
 
Complex skin wounds require long hospitalization periods and cause an ever-growing 
burden on healthcare costs. Moreover, the incidence rates of diabetes, obesity, venous 
insufficiency, and peripheral artery disease show an upward trend as the population ages. 
WHO estimates that now 346 million people in the world suffer from diabetes and that 
diabetes deaths will double between 2005 and 2030. Notably, 15% of these diabetic patients 
will develop a chronic wound at some point in their lives (Frykberg, 1999). 
 
2.9 Surgical treatment of complex skin wound by skin transplantation  

The gold standard treatment for skin defects is transplantation of a split-thickness skin 
graft (STSG). Meshing the graftby making lengthwise rows of short, interrupted cuts, enables 
larger defects to be covered. Meshed grafts also provide more efficient drainage of wound 
exudate and conform better to irregular surface contours. Meshing, however, creates holes, 
interstices, that must be filled by keratinocyte proliferation and migration from the 
surrounding graft; scarring is common when mesh-size is larger. Micrografting is an 
alternative method for standard STSGs (reviewed by Biswas et al., 2010). Meek (1965) 
developed a micrografting method, in which an STGS is sliced with a microdermatome to 
create small cell islands which are transplanted to the wound with or without a carrier. These 
cell islands have a greater surface area in relation to size, making cell migration from the 
margins more efficient. Moreover, MEEK-micrografting provides more accurate expansion 
rates compared to meshed grafts (Lumenta et al., 2011).  
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Full-thickness skin grafts consist of the epidermis and the entire dermis and serve for 
reconstruction of small wounds of the head, neck, hands, and areas of the genitals and breasts, 
in areas where it is crucial to avoid contracture (Grabb & Smith’s Plastic Surgery, 1997). 
Pinch grafts are full-thickness grafts obtained by inserting a needle superficially in the skin 
and harvesting small pieces of skin with a scalpel. Punch/postage stamp grafts, on the other 
hand, are small full or split-thickness grafts cut into uniform small squares. Punch grafting 
became however less frequent with the improvement in meshing techniques (Biswas et al., 
2010) 
 
Harvesting a skin graft creates a donor-site wound (Lagus and Vuola, 2004). Full-
thickness graft donor sites must be treated either by suturing or covering with an STSG. 
Donor sites of STSGs extend to the superficial dermis and heal well within 2 to 3 weeks by 
re-epithelialization. Donor-site wounds may be painful, and healing can be delayed in elderly 
patients and when the body is under systemic stress. 
 
 
2.10 Tissue engineering and skin equivalents 
 
Tissue engineering is an interdisciplinary field of science, combining biology, 
medicine, chemistry, and material science, among others, to develop regenerative therapies 
for replacing damaged or diseased tissues. It is called “a field that applies the principles of 
engineering and the life sciences toward the development of biological substitutes that restore, 
maintain, or improve tissue function”. (Langer and Vacanti, 1993). These researchers 
characterized three general strategies for construction of artificial tissues: 
1.Use of isolated cells or cell substitutes to replace damaged tissues with possible 
manipulation of cells before transplantion. 
2. Application of appropriate tissue-inducing substances and signal molecules, such as 
growth factors, combined with a matrix carrying them to the damaged tissue to control and 
direct regeneration processes. 
3. A carrier matrix (scaffold) with or without cells in a) closed systems, where cells 
are isolated from the body, allowing permeation of nutrients and wastes but preventing 
antibodies or immune cells from destroying the implant. In b) open systems, where the 
implanted matrix and cells are in direct contact with the recipient site and eventually become 
incorporated into surrounding tissues.  
Attempts to create tissue-engineered skin by cell culturing with biological and 
synthetic materials have been made during the last decades (Table II). However, even though 
much is now known about the cellular interactions that guide skin regeneration, reconstruction 
of the anatomy and physiology of healthy skin embracing all crucial elements, is not yet 
possible (Metcalfe and Ferguson, 2007).  
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Figure 6. A schematic picture describing the basic concept for tissue engineering. Adapted from 
Corona et al. Regenerative medicine: basic concepts, current status, and future applications. J Investig 
Med 2010;58:849-58. Used with permission of copyright holder. 
 
2.10.1 ECM scaffolds for tissue engineering and skin regeneration 
Tissue-engineered dermal scaffolds mimic ECM structures and serve in guided tissue 
regeneration; a process in which the three-dimensional structure of the scaffold provides the 
correct milieau for host cell ingrowth and proliferation and subsequent regeneration of the 
tissue in situ (Figure 6). In addition to the promotion of cell migration, an ideal scaffold should 
provide protection againts water loss and infection. Its also must have adequate elasticity and 
mechanical resistance, and elicit a low immunogenic response (van der Veen et al., 2010). 
The scaffold structure influences various cellular differentiation processes; fibroblasts play an 
important role in guided tissue regeneration. Fibroblasts infiltrate into the scaffold, produce 
ECM proteins, and simultaneously degrade the implanted scaffold. 
Dermal scaffolds are divided into natural biological, constructed biological and 
synthetic substitutes (review by van der Veen et al., 2010). Biological scaffolds are natural 
polymers constructed from such materials as collagen, fibronectin, chitosan, and fibrin. An 
interesting biopolymer for tissue engineering purposes is spider silk. Similarly to collagen, it 
can be produced in large amounts by recombinant techniques and then used for tissue 
engineering (Ruggiero and Koch, 2008; Fredriksson et al., 2009). In general, biopolymers 
elicit low toxicity and a less extensive chronic inflammatory response (Metcalfe and 
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Ferguson, 2007). Constructed biological scaffolds are modified with the addition of specific 
proteins, for example GAGs to improve rigidity. On the other hand, synthetic polymer 
scaffolds can be specifically produced and tailored. Additionally, they can be manufactured in 
large quantities inexpensively and have long shelf-life. Common synthetic absorbable 
materials include polylactic-co-glycolide (PLG), polyglycolic acid (PGA), polylactic acid 
(PLA), and polycaprolactone (PCL).  
Epidermal reconstruction is based on transplantation of either autologous or allogenic 
cultured keratinocytes, which are transplanted as sheets or suspensions on the granulation 
tissue-containing neodermis that forms when the scaffold is degraded. Different scaffolds 
used as artificial skin substitutes will be described in the following section. 

2.11 Surgical treatment of complex skin wounds by artificial skin 
substitutes 
2.11.1 Cultured autologous skin substitutes 
 
Cultured autologous skin grafts, frequently referred to as cultured epithelial autografts 
(CEA), consist of sheets of multiple layers of keratinocytes and lack a proper dermis. In the 
1970s, the pioneer work of Rheinwald and Green made cell expansion techniques possible 
with the use of irradiated murine fibroblast feeder layers (Rheinwald and Green, 1975). Since 
the 1980s, this method has been clinically succesful for extensive skin defects such as burns 
(Green et al., 1979; Green, 1991; Wood et al., 2006). O’Connor et al. (1981) first reported the 
use of cultured epithelial autografts in the treatment of major burns. Various commercial 
products gradually emerged, but use of CEAs was limited due to mechanical fragility, lengthy 
cultivation periods, poor take and expensive price (Wood et al., 2006). Because CEAs lack 
dermal-epidermal junctions, complexes needed for connecting the epidermis to the dermis, 
they may adhere poorly to wound beds of variable composition (remnants of fat, muscle, 
fascia, dermis, or granulation tissue). Additionally these sheets are mechanically instable and 
prone to spontaneous blistering (Hefton et al., 1986; Hunyadi et al., 1988; Christiano and 
Uitto, 1996). Among the first commercial products to arise from this technology was 
EpiCel™. Although Epicel is made from autologous keratinocytes, it can be considered a 
xenotransplantation product. Manufacturing is made by co-cultivation of keratinocytes with 
proliferation-arrested mouse 3T3-fibroblast feeder cells. Epicel can be combined with 
petrolatum gauze to form transplantable keratinocyte sheets (Wright et al., 1998; Carsin et al., 
2000). 
 
The initial observation that CEAs were prone to infection and were mechanically 
fragile, led to development of keratinocyte suspension therapy. The hypothesis was that 
keratinocytes remain in a migratory non-differentiated state when seeded as suspensions and 
thus may be more efficient for re-epithelialization. These treatments were also cheaper, 
required less manual labour, and were rapidly and easily obtainable. Hunyadi et al (1988) first 
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described the addition of a fibrin matrix enhancing keratinocyte suspension adhesion to the 
wound bed. When fibroblasts were added as a supporting layer, adherence of transplanted 
cellular grafts onto wounded skin was even more efficient (Currie et al., 2001). Autologous 
keratinocyte stem cells can also be retrieved from hair follicles. EpiDex™ technology utilizes 
these cultured stem cells for transplantation and wound therapy (Tausche, 2003). Additional 
alternatives for cell delivery are, Myskin™ a polymer carrier-dressing, (Haddow, 2003) and, 
CellSpray™ a cell suspension spray (Navarro et al., 2000). Due to the lack of dermis, 
suspension treatments are associated with the same problems as are other CEAs. 
 
Cultured skin substitute (CSS) is a CEA with an additional autologous dermal cell 
layer (Boyce et al., 2006). The culturing of autologous fibroblasts and keratinocytes together 
in a human collagen and glycosaminoglycan scaffold produces a skin substitute with an 
improved anatomical structure. However, the presence of melanocytes in the culture may 
cause uneven pigmentation (Harriger et al., 1995). Boyce et al (1995) observed an average 
take of 75% for the CSS in the treatment of full-thickness burns. After 1-year follow-up, 
however no differences occurred in the healing of autograft- or CSS-treated wounds (Boyce et 
al., 1995). Commercially available alternative technologies include: TissueTech™ (an 
esterfied hyaluronic acid matrix with autologous fibroblasts and keratinocytes), VCT01™ (an 
autologous fibroblast-derived ECM with overlaying keratinocytes), and LOEX skin substitute 
(similar to VCT01™). Autologous bilayer substitutes produce better healing but are restricted 
by their long culturing periods and expense. 
 
2.11.2 Allogenic grafts 
 
By definition, allografts are transplants between genetically nonidentical individuals of 
the same species. De-epithelialized dermal allografts (DED) are produced from human 
cadaveric donors. The acellular structure of DED serves as a scaffold for ingrowth of wound 
bed fibroblasts and endothelial cells. Additionally, it provides a barrier for deep partial-
thickness wounds (Dalla Vecchia et al., 1999). Prior to application, the DEDs must be 
cryopreserved, lyophilized or glycerolized to remove all possible donor-derived cellular 
material, which could be infectious or antigenic. Wainwright observed that the combined use 
of an acellular dermal autograft AlloDerm™, with STSGs allowed use of thinner autologous 
grafts and improved their take (Wainwright, 1995).  
 
Human amniotic membrane consists of a single epithelial layer, a thick basement 
membrane, and an avascular stroma. Underlying the epithelial layer and basement membrane 
is the spongy stromal compartment containing hydrated proteoglycans, glycoproteins, and 
collagen III that form a reticular network (Aplin et al., 1985). Epithelial cells can be cultured 
on a de-epithelialized amnion scaffold, a method used in reconstruction of cornea and skin 
(Yang et al., 2006). Additionally, amniotic membranes provide protection from evaporative 
loss and are effective as temporary wound dressings (reviewed by Kesting et al., 2008). Due 
to possible transmission of some infectious agent, only a fraction of deliveries are eligible for 
collection of amniotic membranes; moreover, storage conditions unfavorably modify its 
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properties (Niknejad et al., 2008). Due to cost-efficiency membranes are still popular in 
developing countries for the treatment of burn patients, and have been advocated especially 
for the treatment of pediatric burn patients (Ravishanker et al., 2003; Branski et al., 2008). 
 
Addition of allogenic fibroblasts to a dermal substitute enhances its wound-healing 
properties through synthesis of ECM components and production of growth factors. 
Moreover, this results in better cosmetic results and less scarring (Purdue et al., 1997 and 
Lukish, 2001). Dermagraft™, a knitted biodegradable PGA/PLA mesh containing human 
neonatal fibroblasts releases growth factors (including FGF-1, -2 and -7, HGF, IGF, PDGF α 
and β, TGFβ, VEGF). It is one of the few products indicated for the treatment for chronic leg 
ulcers (Marston, 2004). ICX-SKN is a dermal substitute comprised of human neonatal 
fibroblast-produced collagen scaffold (Boyd et al., 2007). TransCyte (formerly known as 
Dermagraft-TC), on the other hand, uses a temporary silicone membrane and a nylon mesh 
covered with porcine dermal collagen incorporated with neonatal fibroblasts. Dermagraft™ 
and ICX-SKN are biodegradable, an obvious advantage over the nondegradable TransCyte. 
Storage by cryopreservation reduces cell viability and subsequently growth factor production 
of the Dermagraft™ scaffold and hinders its effectiveness (Mansbridge et al., 1998). 
 
Composite allografts are the most advanced products currently commercially 
available. Their structure closely resembles that of normal human skin. Apligraf® uses a 
combination of bovine type I collagen gel with living neonatal fibroblasts as the dermal 
component and a cornified epidermal layer composed of human foreskin-derived neonatal 
keratinocytes (Trent and Kirsner, 1998). The product is approved by the FDA for the 
treatment of chronic wounds and has been commercially available for several years. Falanga 
et al (1998) published a prospective, randomized, multicenter study of 293 patients, in which 
the efficacy of Apligraf® was compared with compression therapy for the treatment of chronic 
venous ulcers. In a follow-up for 6 months, patients receiving treatment with Apligraf® were 3 
times as likely to experience complete healing of chronic ulcers due to venous insufficiency. 
Similar results were published later by the same authors in a prospective, randomized, 
controlled trial of 120 patients who showed complete healing of a difficult venous ulcer with 
standard compression versus Apligraf® (Falanga and Sabolinski, 1999). Orcel® is an 
analogous bilayered cellular product with a collagen-coated bovine collagen sponge as its cell 
scaffold. Allogenic dermal fibroblasts are cultured within the porous sponge and allogenic 
keratinocytes are seeded in the collagen gel to prevent ingrowth of cells to the scaffold 
(Eisenberg and Llewelyn, 1998). However, less clinical data are published than for Apligraf®. 
 
2.11.3 Advanced wound dressings 

The epidermal barrier can be temporarily restored with different advanced wound 
dressings. Suprathel® is an acellular synthetic dressing composed of a copolymer of DL-
Lactide trimethelcarbonate and α-caprolactone. It is water permeable, permits transfusion of 
excess moisture, and degrades gradually (Uhlig et al., 2007). It can effectively cover STSG 
donor sites and partial-thickness burns (Uhlig et al., 2007; Schwarze et al., 2007). Clinical 
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reports indicate that pain and bleeding associated with dressing changes is significantly lower 
but re-epithelialiazation time is unaffected (Uhlig et al., 2007; Kaartinen and Kuokkanen, 
2011). Martiderm® on the other hand is composed of bovine collagen types I, III, V, and 
elastin. It is used to treat partial or full-thickness burns. 
 
Bilayer substitutes function as dermal templates that promote ingrowth of host cells. In 
addition to the dermal component, commonly composed of animal-derived collagen, an 
epidermal layer helps to protect the wound from moisture loss. Developed back in the 1970s, 
Biobrane® and the Integra® Dermal Regeneration Template (DRT) are the most frequently 
used. Biobrane consists of a bi-laminate nylon mesh membrane bonded to a thin layer of 
silicone. The nylon mesh is coated with porcine type I to support granulation tissue formation, 
and the silicone layer performs the function of the lost epidermis. Although initially designed 
for the treatment of deep complex wounds, Biobrane is now generally regarded as a dressing 
for superficial burns (Greenwood et al., 2009).  
 
Research done by Yannas and Burke, led to the development of Integra® DRT (Burke 
et al., 1981), an acellular scaffold composed of an outer silicone elastomer sheet and a bovine 
collagen and chondroitin-6-glycosaminoglycan dermal template. Integra®DRT promotes 
fibroblast and endothelial cell ingrowth from the host wound bed, and gradual remodeling of 
the matrix creates a neodermis. The dermal component is incorporated into the wound bed 
within 3 to 6 weeks (Stern et al., 1990). When the matrix is adequately vascularized, the upper 
silastic sheet is removed, and ultra-thin skin grafting is performed. Problems in these off-the-
shelf products are their high price, potential for infection, and the need for secondary 
operations. 

2.11.4 Xenografts 
 
Xenograft, tissue taken for transplantation from another species, can serve as either 
temporary coverage for wounds or as templates for tissue regeneration. De-epithelialized 
xenografts that do not support cell ingrowth are intended mainly for temporaty coverage of 
clean partial-thickness wounds (Chiu and Burd, 2005). Recent modifications to porcine-
derived de-epithelialized dermis include aldehyde cross-linking and impregnation of silver 
ions to enhance the grafts antimicrobial properties (Chiu and Burd, 2005). Commercial 
xenografts that support cellular ingrowth are Permacol™, an acellular porcine dermal 
collagen, and Oasis™, an acellular porcine small intestine submucosa-based product. Reports 
of Oasis suggest enhanced healing of chronic venous ulcers (Romanelli et al, 2010). 
Permacol, however, is mainly used as a treatment for hernias repair; the FDA considers is 
unsuitable for the treatment of chronic wounds (Mostow et al., 2005; Romanelli et al., 2010). 
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2.12 Growth factor therapy for epithelial regeneration 
 
Various reports show that active growth factor levels drop decrease in non-healing 
wounds (reviewed by Barrientos et al., 2008). In extensive skin damage, substantial tissue loss 
compromises dermal reactivity, thus delaying reepithelialization by lack of dermal signals, 
and subsequently hindering final healing. Clinical experience on growth factor 
supplementation to accelerate wound healing, however has been discouraging (reviwed by 
Robson, 1997). Presently only three growth factors are effective in patient treatment: PDGF-
BB, FGF, and GM-CSF. PDGF-BB is the only growth factor that has successfully completed 
randomized clinical trials in the United States, and is indicated for treatment of chronic 
wounds. 
 
First reports in by Brown et al (1989) indicated improvement of wound healing by 
topical EGF treatment. Clinical trials later confirmed that wound treatment with topical EGF 
increases epithelialization and granulation tissue formation in venous ulcers. (Falanga et al., 
1992). Moreover a randomized placebo-controlled multicenter study, Fernández-Montequín et 
al (2009) showed that intra-lesional injections of recombinant human EGF significantly 
increase granulation tissue formation and accelerate wound closure of diabetic ulcers.  
 
A promoter of keratinocyte migration, KGF, has been studied for its possible clinical 
use in chronic wounds. Palifermin (rh-KGF) received approval by the FDA for treatment of 
oral mucositis in patients with hematologic malignancies who receive high doses of 
chemotherapy (Weigelt et al., 2011). Furthermore, a trial using topical application of 
Repifermin (rh-KGF2, FGF-10) resulted in accelerated healing of patients suffering from 
venous ulcers (Robson et al., 2001) and showed good results in a Phase II clinical trial.  
 
TGF-β has been studied intensively, since various studies have shown it to be 
decreased due to degradation by proteolytic enzymes, particularly neutrophil elastase (Gill 
and Parks, 2008). Early work with TGF-β on the treatment on venous stasis ulcers was 
promising, but multiple trials have failed to prove efficiency for the treatment of chronic 
wounds (Robson, 1995). 
 
 Recombinant human PDGF-BB (becaplermin; Regranex®) gel was approved by the 
FDA for treatment of deep lower-extremity diabetic neuropathic ulcers that extend to the 
subcutaneous tissue.  It has been applied with success in diabetic and pressure ulcers, being 
the only FDA approved drug for chronic wound treatment (Wiemann et al., 1998), and PDGF 
gene therapy has been applied for treatment of patients with diabetic ulcers (Margolis et al., 
2004; Jinnin et al., 2005). 
 
GM-CSF is increased in the epidermis of wounded skin, taking part in recruitment and 
activation of neutrophils during its inflammatory stage (Mann et al., 2001). Additionally, GM-
CSF increases keratinocyte proliferation both directly and by up-regulation of IL-6 
production.  In patients with diabetic ulcers, because subcutaneous injections of GM-CSF 
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showed faster healing, the general opinion is that it could be of potential use for treatment of 
chronic wounds (Bianchi et al., 2001). In a randomized, blinded, controlled study by Marques 
et al (1997) GM-CSF proved to promote healing of leg ulcers when injected perilesionally. 
Wu et al (1997) studied the mechanisms by which wound healing are upregulated by GM-
CSF. It seems that GM-CSF causes the generalized enhancement of activation of the tissue 
macrophage via upregulation of TGF-β. Recombinant human GM-CSF is sold as Leucomax 
(molgramostin) and Leukine (sargramostin). 
 
2.12.3 Cell-lysate based products 
 
Platelet-rich plasma (PRP), an autologous plasma-derived platelet suspension, has 
served as a wound treatment for over two decades. In addition to its function as a tissue 
sealant, PRP contains a broad range of growth factors, which are released by degranulation 
from the platelets. The composition of the product varies depending on the protocol, by which 
the platelet are collected, but at least PDGF-AA, BB, and AB isomers, TGF-β, platelet factor 
4, IL-1, platelet-derived angiogenesis factor, VEGF, platelet-derived endothelial growth factor 
(PDEGF), EGF, epithelial cell growth factor (ECGF), and IGF have been found in PRP 
(reviewed by Lacci and Dardik, 2010). In a multicenter trial, autologous PRP was used for the 
treatment of diabetic foot ulcers in 72 patients with type I - or type II diabetes (Driver et al., 
2006). After a 12-week treatment period with either PRP or normal saline gel, the authors 
observed that 68.4% of patients in the PRP-group versus 42.9% in the saline group had 
complete wound closure. The inconsistent methodologies in producing PRP make it difficult 
to directly compare different studies. 
 
2.13 Tissue engineering of carrier matrices for topical treatment with 
growth factors 

In addition to their use as dermal scaffolds, fibrin, collagen and gelatin can be 
combined with growth factors produced by recombinant technologies in yeast or bacteria to 
provide a slow-releasing high-concentration carrier for topical treatment of wounds (Uebersax 
et al., 2009).  
 
Collagen 
Collagen has been used extensively in bioengineering, and various animal-derived 
collagen-based skin substitutes have been introduced during recent years (Metcalfe and 
Ferguson, 2007). Twenty five types of collagen exist, with types-I, II, and III present most 
abundant in tissues. Collagens I, II, and III form rod-like right-handed triple helices consisting 
of three coiled subunits composed of two alpha and one beta chain, which are synthesized 
predominantly by fibroblasts, epithelial cells, osteoblasts, and chondrocytes (Hulmes et al., 
1973). Besides providing structural and mechanical properties to tissue, collagens can interact 
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with growth factors and cytokines (Friess, 1998; Kanematsu et al., 2004). For controlled 
release, the therapeutic agent is bound into collagen structures by hydrogen bonding, covalent 
bonding or simple entrapment (Lee et al., 2001). Release of factors is facilitated by enzymatic 
cleavage of the collagen scaffold by collagenases produced by cells such as macrophages and 
fibroblasts. However, manipulation of collagen by chemical crosslinking makes it more 
resistant to this effect (Itoh et al., 2002; Uebersax et al., 2009) and concentrated collagen 
hydrogels seems to be more resistant to degradation (Helary et al., 2010). 
 
Gelatin 
Collagen degradation produces gelatin. Both collagen and gelatin are considered 
biodegradable scaffolds. In addition to biodegradability, dehydration of gelatin produces a 
porous sponge, which can be used for cell culture. Macroporous biodegradable gelatin spheres 
offer a novel alternative for dermal reconstruction. Cultivation of ecto- and mesodermal 
lineage cells has been successful (Huss et al., 2007). In an in vivo experiment, intradermally 
injected gelatin spheres stimulated dermal regeneration and degraded gradually within 26 
weeks of the injection (Huss et al., 2010). Gelatin is generally considered mechanically 
instable, but cross-linking with GAGs has been show to improve its fragility and ease 
handling (Choi et al., 1999). 
 
Fibrin 
 
Fibrinogen is a large and complex glycoprotein consisting of three polypeptide chains 
linked together by 29 disulfide bonds. Thrombin cleaves serum fibrinogen to form an 
insoluble fibrin polymer (Mosesson, 2005). A wound-sealing fibrin clot forms when fibrils 
aggregate Ferry, 1952). Fibrin is also one of the proteins taking part in the formation of a 
provisional matrix found in granulation tissue (Clark et al., 1982) and it is used commonly in 
surgery as a wound sealant and tissue adhesive. Fibrin has several advantages as a growth 
factor delivery matrix for clinical use due to its low host reaction and immune responses 
(Spiker and Mikos, 2010); a hydrogel is easily inducible by mixing fibrinogen with thrombin 
before application. Various growth factors such as FGF and EGF can be easily incorporated in 
a fibrin matrix and both fibrinogen and thrombin concentrations affect their release (Jeon et 
al., 2005). Pandit et al (1998) reported that FGF 1-loaded fibrin matrices significantly 
improved the mechanical properties of the regenerated tissue in full-thickness wounds in 
rabbits after 2 weeks. Moreover, Geer et al (2005) showed that application of fibrin-bound 
KGF to skin wounds increased epithelialization in athymic mice (Geer et al., 2005). Fibrin 
matrices are thus under investigation for use in growth factor therapy, cell culture, and tissue 
engineering (Spotnitz and Prabhu, 2005). 
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Electrospinning 
Because the dermis is principally composed of nanoscale fibers of collagen providing 
structural integrity and mechanical strength, recent focus of tissue engineering has been the 
development and fabrication of ECM analogues composed of nanoscale fibers. The method, 
electrospinning, involves the application of an electrostatic force between the polymer 
solution and a counter metal electrode, which is kept at a certain distance. Resulting in porous 
nanofiber (poresize 1-10μm) matrices that mimic the structure of native ECM and can be 
produced simply and rather inexpensively. The use of electrospun scaffolds as a wound 
dressing or cellular carrier for skin substitutes has been suggested for a variety of materials 
including collagen, gelatin, fibrinogen, PCL and PLA (Powell et al., 2008; Kumbar et al., 
2008). Even though extensive in vitro work has been made to prove the efficiency of 
elecrospun materials as tissue scaffolds or skin constructs for wound treatment, very limited 
in vivo applications have been reported and further research is needed to prove the clinical use 
of these products (Chong et al., 2006).
 
2.14 Fibroblast aggregation as an activator of growth factor production 
 
The inflammatory response has long been considered pivotal to providing growth 
factor and cytokine signals orchestrating the cell and tissue movements vital for skin repair. A 
central link in this process is the activation of fibroblasts, characterized by vast production of 
proinflammatory cytokines as well as cyclooxygenase 2 (COX-2) (Buckley et al., 2001). 
Furukawa et al (2001) described a way to mimic fibroblast activation in vitro with the 
formation of human skin fibroblast aggregates using a rotational culture. These authors 
reported that TGF-β was upregulated in the fibroblast spheroids and suggested that 
combination of fibroblast spheroids in a collagen-coated PGA mesh could improve dermal 
wound healing (Furukawa et al., 2001). Bizik et al (2004) stated that the formation of densely 
packed spheroids initiates a proinflammatory, proteolytic, and growth factor response, a 
process that was designated as nemosis. Fibroblasts were activated by seeding them onto non-
adherent surfaces, such as agarose-coated wells or to “hanging drops” depriving the cells of 
the possibility of adherence to the culture dish (Salmenperä et al., 2008).  
 
A central feature of fibroblast aggregation is the massive induction of COX-2 and 
secretion of prostaglandins (PG): PGE2, 6-keto-PGF1α, PGF2α, and PGD2 (Kankuri et al., 
2005). The cell clustering in nemosis occurs cellular fibronectin interaction with its integrin 
receptors (alpha5 and beta1) via Arginine-Glycine-Aspartic acid (RGD) motif, (Salmenperä et 
al., 2008). Characteristic to the activation of fibroblast aggregates is the production of 
proinflammatory cytokines (IL-1, IL-6, leukemia inhibitory factor (LIF), and GM-CSF) and 
chemokines (macrophage inflammatory protein- (MIP-1α), RANTES, and IL-8) as well as 
growth factors. One particular growth factor HGF, upregulated 1000-fold on the mRNA-level, 
caused mitogenic and motogenic responses of cells expressing the properly processed receptor 
c-Met (Kankuri et al., 2005 and 2008). In addition to upregulation of HGF, VEGF is also 
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evident (Enzerink et al., 2009). Fibroblast nemosis activation (measured as induction of COX-
2 and IL-8) occurs at least in neonatal foreskin, fetal skin and lung, and lung-derived 
fibroblasts (reviewed by Vaheri et al., 2009). 
 
2.15 In vitro model of epidermal wound healing; scratch assay 

The in vitro scratch assay is a feasible and cheap method to study motility of adherent 
cells into cell-free space, mimicking the cell migration seen in wound healing  (Todaro et al., 
1965). A gap -a scratch- is created on a confluent cell culture monolayer mechanically with 
for example the tip of a pipette; movement of cells on the edge of the newly created gap is 
monitored until the empty space between the edges is filled (Haudenschild and Schwartz, 
1979). Images are captured from the same location at regular intervals to determine rate of 
closing of the gap. An advantage of this method is that it can be combined with other 
techniques such as stimulation and inhibition of cell migration with pharmacological agents. 
Additionally, the migration path of individual cells can be monitored with the aid of time-
lapse microscopy and image analysis software. Disadvantages of the scratch assay compared 
to other methods (Boyden chamber, single cell tracking techniques, agarose cell migration 
assay) include a need for large amounts of cells and lengthy cultivation periods to obtain 
confluent monolayers. Cell migration may be also affected by the wounding, which causes 
cell injury or changes in cell-to-cell adhesion, because cells adjacent to the cell-free gap 
become permeable due to disruption of cell-cell junctions. 
 
2.16 In vivo porcine model of skin wound healing 
 
Porcine skin resembles human skin anatomically and physiologically. As for skin 
morphology, both have a thick epidermis and a similar dermal-epidermal thickness ratio; a 
measurement that takes into account body site when evaluating skin properties (Vardaxis et 
al., 1997). Both human and pig skin have well-developed rete-ridges and dermal papillary 
bodies and abundant subdermal adipose tissue (Montagna and Yun, 1964.). Porcine dermal 
collagen is similar (Heinrich et al., 1971) and neither pigs nor humans have a panniculus 
carnosus, an additional striated muscle layer within the subcutaneous tissue, which is seen in 
small loose-skinned animals. This plays a central role in skin healing, because human and pig 
healing occurs largely through re-epithelialization, whereas small animals, rely mainly on the 
panniculus, which causes wound contraction and wound closure.  
 
Some differences exist, however. In pig skin, a less-developed adnexal structure 
supporting the subepidermal plexus and lesser elastin content is apparent (Forbes et al., 1969). 
Additionally, pig skin contains no eccrine glands, and in unlike in humans, apocrine glands 
are distributed throughout the skin surface (Meyer et al., 1978). Functionally, pig and human 
skin are similar in terms of epidermal turnover, keratinous proteins, and lipid composition of 
the stratum corneum. They also share similar immunohistochemical staining for keratins 10 
 37 
and 16, which is useful for describing keratinocyte function and differentiation (Wollina et al., 
1991). Growth factors have mainly similar effects. EGF has been shown to accelerate partial-
thickness skin-wound healing in both pigs and humans (Breuing et al., 1997; Nanney et al., 
1990). Studies on IL-1α and bFGF have shown that the pig proves a superior wound-healing 
model compared to the rat. In pigs and humans, IL-1α significantly enhances epithelial 
healing (Saunder et al., 1990; Mertz et al., 1991), whereas preliminary evidence show that IL-
1α may impair wound strength in rats (Maish et al., 1999). Because the physiology of wound 
healing is similar in pigs and humans, and the anatomical structure is closely related, the pig 
serves as a more reliable model for wound-healing experiments than do other animals 
(Sullivan et al., 2001).  
 
2.17 In vivo human models of wound healing 

Although animal models provide excellent tools for studying wound healing, differences still 
exist, and not all results can be directly translated to humans. However, some in vivo human 
models provide an alternative for animal wound-healing studies. The suction blister model, 
introduced by Kiistala et al. in 1964, utilizes negative pressure to create a subepidermal 
blister. Removal of the epidermis from the blister creates a wound, and wound healing can be 
followed morphometrically (Kiistala and Mustakallio, 1964; Silverman et al., 1989). Healing 
of a skin wound can also be measured by following water loss through the skin. This method, 
trans-epidermal water loss (TEWL), has been useful, particularly in studies of the effect of 
topical treatment and drug reactions.
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3. Aims of the studies 
 
The aim of this thesis was to investigate how paracrine mediators from aggregates of 
dermal fibroblasts and bone marrow stromal cells contribute to epidermal and dermal 
responses during skin wound healing. 
 
The specific aims of the individual studies were to investigate 
 
I aggregation-induced production of HGF in bone marrow stromal cells and to 
characterize its effect on model keratinocyte wound healing in vitro. 
 
II use of fibrin as a controlled-release matrix for delivery of fibroblast aggregate-
derived factors and keratinocytes in vitro. 
 
III the effect of fibroblast aggregate-derived paracrine factors on epidermal healing 
in a porcine partial thickness wound model in vivo. 
 
IV the biocompatibility of recombinant human collagen III for transplantation of 
cultured keratinocytes and dermal fibroblasts in a porcine full-thickness wound 
model in vivo. 
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4. Materials and methods 
4.1 Cells and cell lines 
 
Spontaneously immortalized HPV-negative keratinocytes (HaCaT) (Boukamp et al., 
1988) were from CLS (Cell Lines Service, Eppelheim, Germany). The cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplied with 1% penicillin/streptomycin and 
5% fetal calf serum (FCS) (Sigma-Aldrich). Human dermal fibroblasts (CRL2088, American 
Type Culture Collection, Manassas, VA, USA) produced keratinocyte stimulatory growth 
factors. The cells were cultured in DMEM supplied with 1% penicillin/streptomycin and 10% 
fetal calf serum (FCS) (Sigma-Aldrich, Munich, Germany). The experiments utilized passages 
9 to 16.  
 
Bone marrow aspirates of control patients participating in a clinical cell 
transplantation trial (Clinical-Trials.gov identifier NCT00418418) were used for this study 
with the patient protocols approved by the Ethics Committee of the Helsinki University 
Hospital, Department of Surgery. After signed informed consent and after randomization to 
the study protocol, bone marrow aspirates were taken under general anesthesia from the iliac 
crest of adult patients.  
 
Mononuclear cells in samples from control patients were isolated with a density 
gradient using Ficoll-Paque (Pharmacia, Uppsala, Sweden) as described in Pittenger et al. 
(1999). These cells were resuspended in complete culture medium, DMEM, with low glucose, 
supplied with 1% penicillin/streptomycin, 10% FCS (tested for its ability to support 
mesenchymal stem cell expansion, StemCell Technologies, Vancouver, BC, Canada) and then 
plated at a density of 0.36 x 106/cm2, and incubated under standard cell culture conditions 
(37C° with 5% CO2). After 2 days, the adherent cells were washed thoroughly with 
phosphate-buffered saline (PBS), and were further cultured up to passages three to five in 
complete culture medium. The cells were assayed by flow cytometry (FACSCanto, Becton 
Dickinson, San Jose, CA, USA) with data analysis using FACSDiva software (Becton 
Dickinson). They expressed CD29, CD44, CD105, and CD166, but not CD34, CD45, or 
CD14 (data not shown). The multilineage differentiation potential of cultured cells was 
assessed through the differentiation ability of cells into adipocytes and osteoblasts. For 
osteogenic differentiation, cells were plated at 3x103/cm2 and cultured in DMEM with 10% 
FCS, 10mM β-glycerophosphate, 10-7 M dexamethasone, and 200 μM ascorbic acid- 2-
phosphate. The medium was changed every 3 to 4 days, and after 21 days, cells were analyzed 
by von Kossa staining. For adipogenic differentiation, the cells were grown to confluence and 
cultured for 48 to 72 hours in DMEM with 10% FCS, 0.5mM isobutylmethylxanthine, 1 μM 
dexamethasone, 10 μM insulin, and 200 μM indomethacin. After this, the medium was 
changed for maintenance medium containing DMEM with 10% FCS and 10 mM insulin for 
24 hours. This was repeated twice and cells were analyzed by Oil Red-O staining. Eventually, 
the cells showed osteogenic and adipogenic differentiation potential. 
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Primary keratinocyte cultures were created from surgical waste from healthy female 
donors undergoing breast reduction surgery. The protocols for collecting patient skin samples 
were approved by the Ethical Review Board of the Helsinki University Central Hospital 
(approval #431/E6/06). After receiving each patient’s informed consent, biopsy specimens of 
skin were collected and kept moist at +4°C for a maximum 24 h before use. The samples were 
first washed with phosphate-buffered saline (PBS), then subcutaneous fat was removed, and 
skin pieces 1 mm wide, containing epidermis and dermis, were excised for further processing. 
Epidermal detachment was performed with overnight incubation in PBS containing 1.45 U/ml 
dispase (Dispase™, Roche, Mannheim, Germany). After incubation, the epidermis was peeled 
off and was incubated further at +37°C with 0.1% trypsin in PBS for 5 min. A single-cell 
suspension was obtained by vigorous pipetting to mechanically dissociate the epidermal 
sheets. Thereafter, cells were seeded in gelatin-coated flasks for further propagation. Cells in 
passages one to three served in the experiments. Primary keratinocytes were grown in defined 
keratinocyte serum-free medium (K-SFM) (Invitrogen, Life Technologies, Carlsbad, CA, 
USA) supplied with 1% penicillin/streptomycin. 
 
4.2 Reagents 
 
HGF-neutralizing antibody was from R&D Systems (Minneapolis, MN, USA). 
Recombinant human HGF (rhHGF) was from PeproTech Inc. (Rocky Hill, NJ, USA). Human 
epidermal growth factor (EGF) was from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, 
USA). PGI2 analogue, 6a-PG(PGI2), was from CaymanChemical (Cayman Chemical 
Company, Ann Arbor, MI, USA). Pharmacological PI3K inhibitors were LY294002, its 
structural inactive analogue LY303511 (Calbiochem, Nottingham, UK), and wortmannin 
(Calbiochem). Two selective small-molecule Met-kinase inhibitors, SU11274 (Wang et al 
2003, Ma et al 2005) and PHA665752 (Calbiochem, Nottingham, UK) as well as two small 
molecule EGF-receptor tyrosine kinase inhibitors: PD153035 hydrochloride (Tocris 
Bioscience, Ellisville, MO, USA) and AG1478 (Tocris Bioscience) were used at indicated 
concentration to show HGF and EGF-linked keratinocyte-fibroblast responses in vitro. 
Inhibitors of MEK, ERK1/2, and p38 were respectively: PD98059, U0126, and SB203580 (all 
from Calbiochem).  
 
4.2.1 Production of the paracrine mediators from fibroblast aggregates 
 
Multicellular spheroids were generated as described (Bizik et al., 2004). Briefly, U-
bottomed 96-well plates (Costar, Cambridge, MA, USA) were treated with low-
electroendosmotic agarose (Lonza, Basel, Switzerland) prepared in sterile water to form a thin 
film of a nonadhesive surface. BMSCs were seeded at 8,000 cells per spheroid in 200 μl 
DMEM with 10% FCS. Spheroid formation was allowed to proceed for 3 days. The spheroids 
were collected, allowed to settle spontaneously by gravity, and were washed with serum-free 
medium. When spheroids were formed from dermal fibroblasts, 15 x 103 cells per well in 80 
μL DMEM with 5% FCS were used.  
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4.3 Enzyme-linked immunosorbent assay (ELISA) 
 
Conditioned medium from cell cultures was harvested to determine HGF and 
Aphiregulin production by BMSC as well as CRL-2088 spheroid- or monolayer cultures. 
Growth factor concentration was estimated by the Amphiregulin and HGF ELISA kit (R&D 
Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. The absorbance 
of ELISA-plates was read at λ = 450 nm using a multiscan ELISA plate reader (Multiskan™, 
Thermo Scienfic). A standard curve was created using different concentrations of a stock 
human HGF and amphiregulin protein, which served as a positive control. The protein 
concentration of the sample was determined by regression analysis compared to the standard 
curve; the lab technician did the analysis. 
 
4.4 Immunoblotting 
 
Immunoblotting was carried out according to the standard protocol (Bizik et al., 2004). 
Cell samples were lysed directly in sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) sample-loading buffer supplemented with complete 
miniprotease inhibitor mixture tablets (Roche, Mannheim, Germany). The samples were 
separated in SDS-PAGE (gradient of polyacrylamide 5-15%, 3.5% stacking gel) and then 
transferred nitrocellulose membranes. The bound immunocomplexes were detected by 
alkaline phosphatase-conjugated secondary antibodies and reagents (Promega, Madison, WI, 
USA). Visualization of bands was performed according to manufacturers’ recommendations. 
The following primary antibodies served for immunoblotting: rabbit monoclonal antibody 
against c-Met (Neomarkers, Fremont, CA), rabbit monoclonal antiphospho-Met (Y1234, 
Y1235) (Upstate Biotechnology, Lake Placid, NY, USA), rabbit polyclonal antibody against 
COX-2 (NeoMarkers), and mouse monoclonal antibody against actin (NeoMarkers). 
 
4.5 Immunofluorescence 

Deparaffinized 4-μm sections of porcine skin served for immunohistochemical 
analysis in the partial-thickness wound-healing studies. PCNA was detected using the 
monoclonal anti-PCNA-antibody (Neomarkers) with a secondary Alexa fluor 555 anti-rabbit 
antibody (Invitrogen). Cytokeratin-14 (K-14) was analyzed with a fluorescein isothiocyanate 
isomer I (FITC) -labeled mouse anti-human cytokeratin-14 antibody (Abcam, Cambridge, 
UK). Analysis was done with the AxioCam Imager M2 microscope and with an AxioCam 
HRm digital camera (Carl Zeiss Vision GmbH, Aalen, Germany). Mouse anti-human 
pankeratin (diluted 1:40, Millipore, Billerica, MA, USA) antibody was used to characterize 
transplanted keratinocytes in the wound bed. DAB (3,3-diaminobenzidine) served as the 
chromogenic substrate for horseradish peroxidase (HRP) for visualization of pankeratin-
positive cells. 
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4.6 Green fluorescent protein (gfp) transfection 
 
HaCaT keratinocytes cells were labeled with green fluorescent protein (gfp) by 
transfection with a lentiviral vector carrying the gfp gene and 8 μg/mL polybrene for 24 h to 
create fluorescent HaCaT cells (gfp-HaCaT) for further experiments. The lentiviral vector was 
a kind gift from Professor Seppo Ylä-Herttuala (AIV Institute, Kuopio, Finland). 
 
4.7 Keratinocyte assays 
4.7.1 Scratch wound assay and co-culture stimulation of keratinocyte migration 
 
Confluent HaCaT cell monolayers were serum starved after washing with PBS. After 
1 day of serum starvation, the monolayers were scratch-wounded by the tip of a spatula, and 
washed multiple times with PBS; treatment was initiated one day after wounding. In the co-
culture setting spheroids and the corresponding amount of mesenchymal cells were plated on 
Transwell inserts (Corning Life Sciences, Lowell, MA, USA) for physical separation of the 
HaCaT-cell co-culture. The experiments were continued without change of medium after 
placement of inserts upon the monolayer.  

4.7.2 Characterization of intracellular signaling cascades 

Growth factor inhibitors (SU11274, anti-HGF, LY294002, PD98059, SB203580, 
LY303511, U0126) were added to the wounded keratinocyte monolayer at the time of 
stimulation with recombinant growth factors (HGF, EGF) or with conditioned medium from 
BMSC spheroids (collected 3 days after initiation of spheroid formation). Use of conditioned 
medium prevented any effect which the inhibitors might have had on nemosis. Later on, a 
scratch wound assay validated the use of SU11274 as an inhibitor for both HGF- and EGF-
linked migration with primary keratinocytes monolayers. Stimulation of cell migration was 
then initiated with rhHGF and rhEGF with or without SU11274. 
 
For analysis of cell migration on the fibrin matrix, multicellular gfp-labelled HaCaT 
cell spheroids were formed in U-well plates and seeded on top of a fibrin gel which  contained 
conditioned from spheroid or monolayer- cultures. 
 
 
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4.7.3 c-Met phosphorylation 

Conditioned medium from BMSC spheroids stimulated HaCaT cell monolayers and 
samples were collected at 0 hour, 0.5 hour, 1 hour, 2 hours, and 3 hours to detect 
autophosphorylation of c-Met with an antiphospho-Met (Y1234, Y1235) antibody 
(Neomarkers). 
 
4.7.4 MTT and gfp-fluorescence assay as measurement of cell viability 

Cell respiration, an indicator of cell viability and cell growth, was assayed by the 
mitochondria-dependent reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) to formazan (Roche, Mannheim, Germany). At selected time points, the 
cultures were incubated with the substrate (5 mg/mL) for 90 min, after which the medium was 
aspirated, and MTT was dissolved in DMSO. The extent of MTT conversion to formazan was 
quantified by measurement of optical density at 550 nm with a wavelength correction of 690 
nm, by a microplate reader (Multiscan MCC/340, Labsystems, Helsinki, Finland). Gfp-
HaCaT cells allowed analysis of growth factor-induced keratinocyte proliferation. Viability 
and size of cell populations were measured and photographed with a fluorescence microscope. 
Before each measurement, plates were washed twice with PBS to remove unattached cells 
from the lattice. Eventually, fluorescence signal intensity was assessed with ImageJ 1.41 
software (U.S. National Institutes of Health, Bethesda, MA, USA, http://rsb.info.nih.gov/ij). 
 
4.8 Carriers for fibroblast-derived paracrine factors and cell 
transplantation 

4.8.1 Fibrin matrix 
 
The fibrin matrix was formed from commercially available fibrin sealant Tisseel Duo 
Quick from Baxter Healthcare, Deerfield, IL, USA. Both components of Tisseel were diluted 
with conditioned medium or with PBS for optimization of cell growth and proliferation. After 
mixing of the diluted solutions, the solid gels were further used as carrier matrices for 
fibroblast-derived soluble factors both in the in vitro and in vivo studies. 
 
To demonstrate the binding and release characteristics of finectra from the fibrin 
matrix, the conditioned medium was collected and dialyzed with a Slide-A-Lyzer 2k dialysis 
cassette (Thermo Scientific, Carlsbad, CA, USA) according to the manufacturer’s protocol to 
remove salts, then lyophilized and labeled with a red fluorescent dye label, DyLight 594 
(Thermo Scientific). A fibrin matrix was constructed with the labeled proteins as described 
previously.  Released fluorescence was quantified with a fluorescence reader (340 nm/ 460 
nm; Wallac Victor2, PerkinElmer Life Sciences, Waltham, MA, USA). For confocal imaging, 
DyLight 594-labeled protein and FITC (Sigma) were incorporated within the fibrin matrix 
during the polymerization. Confocal microscopy was carried out using a Leica TCS SP2 
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AOBS system (Leica Microsystems AG, Wetzlar, Germany) with argon 488 nm or DPSS 561 
nm excitation lines, and an HCX PL APO CS 63x/1.40 NA objective. Image stacks were 
acquired through the matrices at a 240 nm z-sampling density. 
 
4.8.2 Recombinant human collagen III (rhCol-III) matrix 

RhCol-III dilute solutions (0.3% of w/w) came from FibroGen (FibroGen Inc., San 
Francisco, CA, USA) with a pH of approximately 2 (in 0.01 mol/l hydrochloric acid). After 
adjusting the pH to 7.2 with a fibrillogenesis buffer (Na-phosphate, pH 11.2 adjusted from 7.2 
to 11.2 with concentrated NaOH) a collagen hydrogel was obtained with a final collagen 
concentration of 1.5 mg/ml. The solution was pipetted in 96-well plates, 100 μl per well, and 
then placed in a centrifuge at 10,000g for 1 h, whereafter excess liquid was carefully removed 
and a thin rhCol-III coating (final concentration, 50 mg/ml) formed in the bottom of the wells. 
For cell transplantation, isolated primary porcine keratinocytes and fibroblasts were cultured 
for one week, then detached with trypsin and seeded into rhCol-III containing syringes in 
separate layers of different cell amounts. Each syringe contained a total of 500x103 cells; the 
keratinocyte group comprised of 500x103 keratinocytes, and the co-culture group of 250x103 
keratinocytes and 250x103 fibroblasts in separate layers. 
 
4.9 Porcine wound healing assay 
4.9.1 Animal care and ethical statement 

All animals were maintained and treated in accordance with the Principles of 
Laboratory Animal Care of the National Society for Medical Research and the Guide for the 
Care and Use of Laboratory Animals by the National Academy of Sciences and published by 
the National Institutes of Health (NIH publications No. 8623, revised 1985). This study was 
approved by the Operative Ethics Committee of the Helsinki University Central Hospital and 
by the Provincial State Office of Southern Finland (ESLH-2009-03831/Ym-23). All animals 
used in the studies were anesthetized with an intramuscular injection of ketamine (4-6 mg/kg 
s.c.) and medetomidine (0.5 mg/kg s.c.). Anesthesia was continued with intravenous infusion 
of propofol (4-10 mg/kg/h i.v.). The animals received daily doses of broad-range antibiotic 
ceftriaxone 1 g i.m post-operatively. 
 
4.9.2 Partial- and full-thickness wound-healing assays 
 
A simple randomization for the cranio-caudal anatomical location and paravertebral 
sides involved flipping a coin prior to the operation. A series of deep, mirror-image partial-
thickness wounds 4 cm x 5 cm were created by the same surgeon on the lateral paravertebral 
skin of each pig (four wounds per side, total eight wounds per pig) with a Zimmer dermatome 
(Zimmer, Inc., Warsaw, IN, USA) set at 30/1000 in. The wounding procedure created a 
partial thickness injury that extended approximately halfway depth (50%±2%) into the 
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dermis, removing surface epithelium and superficial dermis, but sparing the lower dermis 
containing epithelial appendages such as hair follicles. Estimation of wound depth was 
obtained by measurement of total skin thickness prior to wounding with an 8 mm punch 
biopsy in the center of the wound and by comparing this with the thickness of the skin graft. 
Wounds were followed until the third postoperative day without dressing changes and then 
excised with a margin of 1 cm of unwounded surrounding skin down to the fascia.  
 
In the full-thickness wound-healing assay, after simple randomization, 14 identical 
mirror-image full-thickness wounds were created by the same surgeon on the lateral 
paravertebral skin of each pig with an 8-mm punch biopsy tool, seven wounds per side. 
Treatment was initiated by application of rhCol-III hydrogel with pre-cultured fibroblasts and 
keratinocytes. Untreated wounds were used as controls for the treatment groups. Wounds 
were monitored until the fifth postoperative day without dressing changes. 
 
4.10 Histology 

Paraffin-embedded, hematoxylin and eosin (H&E)-stained 4-μm sections of each 
wound were analyzed and photographed (Leica IM500 and Leica QWIN software; Leica 
Microsystems AG, Heerbrugg, Switzerland). To assure objectivity, sections were coded 
during the operation, and slides were analyzed in blinded fashion for each wound. In partial-
thickness wounds, the histological sections were analyzed for the amount of new epithelium, 
lateral epidermal cell migration, and granulation tissue formation. The new epithelium was 
defined as the area between the wound margins in the wound bed covered by epithelial cell 
islets and cells growing out of regenerating hair follicles. The area between the unwounded 
dermis at the bottom of the wound and newly formed epidermis was considered granulation 
tissue, and the underlying unwounded dermis as total dermis. Lateral migration in the border 
zone was measured morphometrically from the wound margin to the tip of the cells’ leading 
edge. In full-thickness wounds, formation of granulation tissue was evaluated from the wound 
base, and healing of the wounds measured as the reduction in initial wound size. The Sirius 
Red staining–based colorimetric assay was revealed collagen type-I and III deposition in the 
full thickness wounds, an indicator for granulation tissue formation. Total collagen content 
was calculated as percent Sirius Red–stained positive area/wound area from scanned images 
of stained tissue sections by Image J–software (ImageJ, National Institutes of Health, 
http://rsb.info.nih.gov/ij). 
 
4.11 Near-infrared spectroscopy (NIRS) 

In the partial-thickness wound study, a NIRS examination involved a spectrocutometer 
as done previously (Kaartinen et al., 2011; Välisuo et al., 2011). The spectrocutometer 
consists of a single lens reflex camera (Fuji IS Pro, Fujifilm Corporation, Tokyo, Japan), an 
external chamber to block out ambient light, and a built-in computer controlled lighting 
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system that uses both visible and near-infrared light. The spectrocutometer is used to 
measures the estimated concentration changes (ECC) of oxyhamoglobin (oHb), 
deoxyhamoglobin (doHb), and melanin in the wound (Välisuo et al., 2011). 
 
 
4.13 Statistical analysis 

Data were analyzed by Student’s paired t-test (two-tailed) where p < 0.05 was 
considered statistically significant. Case–control wounds were analyzed by the Mann–
Whitney U test. In the study with NIRS-camera analysis, the correlation between the ECC of 
oHb and epithelial thickness was calculated from the pooled data including all wounds, 
regardless of treatment, with Pearson’s correlation coefficient. Statistical analyses were 
performed with GraphPad Prism 4.0 (GraphPad Software Inc, San Diego, CA, USA). 
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5. Results 
5.1 Activation of nemosis in bone marrow stromal cells, defined by COX-2 
expression and HGF production; effect of HGF and amphiregulin on 
keratinocyte migration (Study I, II) 

Reports state that human dermal fibroblast aggregation induces expression of the 
hepatocyte growth factor/scatter factor (HGF) (Bizik et al., 2004; Kankuri et al., 2005 and 
2008). In the first of the studies presented in this Thesis, bone marrow stromal cells collected 
from four healthy donors were evaluated for analogous activation. After assessment for 
multilineage potential, cells were plated on nonadherent U-wells. Cluster formation occurred 
within 24 hours with upregulation of COX-2 and HGF (I).  After 2 and 3 days of culture as 
spheroids, the expression of COX-2 increased 3.8 to 8.2-fold, and on the fifth day a clear 
induction of 62.5-fold was evident as compared with COX-2 expression levels at day 1. 
BMSCs from donors served then for quantification of nemosis-derived HGF. In concert with 
the induction of COX-2, ELISA showed an average 54.8-fold ± 22.9 (range 10.0–97.8) 
induction of HGF production by BMSC nemosis, whereas monolayer cultures produced only 
low HGF amounts (I). Interestingly, the level of HGF induction varied significantly among 
bone marrow samples, suggesting that although nemosis signaling proceeded in all cases, the 
magnitude of the effect was variable. In order to characterize that the HGF produced was 
active, conditioned medium from BMSC spheroids was used to stimulate HaCaT cell 
monolayers to analyze autophosphorylation of c-Met; the western blot revealed the 
phosphorylated c-Met after 30 min of stimulation (I).  
 
The effects of paracrine factors released from activated BMSC on keratinocyte wound 
healing emerged from an in vitro scratch wound assay. BMSC spheroids and the 
corresponding amount of BMSCs were plated on cell inserts for physical separation of the co-
cultures. The HGF-producing BMSC spheroids significantly enhanced keratinocyte migration 
from the border of the wound and accelerated scratch-wound closure compared with BMSC 
monolayers containing a corresponding amount of cells (I). In the wound-healing assay, 
nemosis stimulation showed a clear dose-dependency whereas the stimulation with the BMSC 
monolayer did not (I). The effect of BMSC nemosis-induced keratinocyte migration was 
partially inhibited by an anti-HGF antibody but nearly totally with a specific small molecule 
c-met kinase inhibitor SU11274 in a non-toxic concentration (I).  
 
The inhibitory effect of SU11274 for both HGF and EGF was validated in a wound-
healing assay with HaCaT cells and primary keratinocytes. SU11274 inhibited HGF 
completely and EGF to a lesser extent (I) in HaCaT cells, but also inhibited EGF-induced 
migration in primary cells (II). Furthermore, the intracellular signaling of c-met through PI3K 
was elucidated in an rhHGF (100 ng/ml)-induced wound-healing assay. PI3K-inhibitors were: 
LY294002, wortmannin (I), and LY303511-the inactive structural analogue of LY294002. 
Results indicated that the PI3K inhibitors LY294002 and wortmannin attenuated rhHGF-
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induced wound healing, whereas LY303511 had no effect. Conversely, the effect of inhibitors 
of p38 (SB203580), of ERK 1/2 (U0126), and of MEK 1/2 (PD98059) all revealed inhibition 
of HGF-induced migration (I) (Figure 7).  
 
Based on previous unpublished data from our group we knew that amphiregulin-gene 
is upregulated in the spheroid cultures. Therefore the content of amphiregulin cluster cultures 
was analyzed and revealed a 7-fold increase in its production (II). We designated the 
composition of factors deriving from mesenchymal cell nemosis as “finectra” (study II). 
 
 
5.2 Characterization of the finectra-fibrin matrix (II, III)  
Based on results  as regards fibrin as a carrier for cells and growth factors, the aim of 
the study was to show that a matrix formed from fibrin can incorporate finectra and that such 
an innovative active biological—yet acellular—matrix can support the proliferation, 
migration, and viability of human keratinocytes (II). Conditioned medium from dermal 
fibroblast spheroid cultures was collected and combined with a fibrin matrix. HaCaT 
keratinocyte clusters were seeded on top of the matrix, and outgrowth of cells from the 
spheroids was measured. Interestingly, monolayer-stimulated clusters decreased in size, 
whereas spheroid conditioned medium stimulated outgrowth from cell clusters (II). This 
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Figure 7. Validation of methodological data. Specific inhibitors of HGF-c-MET/EGF-PI3K / MEK 
1/2, ERK ½, and p38 signaling-pathways are marked alongside their site of inhibition. c-Met 
coupling/dimerization with EGFr as a possible means of growth factor signaling. Dashed arrows 
indicate possible routes of HGF/finectra-induced migratory signaling. Red arrows mark inhibition. 
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effect was inhibited with SU11274 (II). The viability of gfp-HaCaT cells and of primary 
keratinocytes seeded on fibrin-matrixes was measured respectively by emitted fluorescence 
intensity and with MTT. The fibrin matrix containing rhHGF or conditioned medium from 
fibroblast spheroids cultures displayed an increase in cell rate and cell survival compared to 
those on the monolayer-conditioned medium (II). 
 
In order to demonstrate binding and release characteristics of the factors in the 
conditioned medium from the fibrin matrix the medium was labeled with a fluorescent dye 
(III). The release of DyLight 594 labeled finectra into PBS was measured with a fluorescence 
reader 2, 8 and 32 h after placing the matrix at room temperature in a shaker. Rapid release 
occurred already after 2 h of incubation. After 2 h of follow-up in a shaker in room 
temperature, 29 ± 0.87% ±SEM of the initial protein was released, at 8 h, 42 ± 3.41% and at 
32 h, 56 ± 3.51%. The fluorescence of the labeled protein remained strong throughout the 
experiment, whereas no fluorescence was observed from the blank fibrin matrix. Confocal 
imaging revealed that the labeled finectra was both bound directly to the fibril structure and 
unbound between the fibril mesh.The data indicated that the initial 2 h-release rate is rapid 
(14.5% per h), but is slowed down at 2 to 8 h (2.2% per h), and remains relatively stable 
thereafter (0.58% per h). Extrapolating from these data, the matrix in vitro would have fully 
released finectra after 108 h (III). These release properties of fibrin are similar to what others 
have reported (reviewed by Spicer and Mikos, 2010). 
 
5.3 Studies characterizing properties of collagen (I, III and IV) and fibrin 
for cell transplantation 
 
A collagen contraction assay revealed, whether fibrin or the addition of fibrin with 
collagen would diminish the contractive properties of cell containing collagen matrixes. 
Additionally the assay defined whether a collagen/fibrin matrix could allow transplantation of 
fibroblast spheroids (II). Fibroblasts or fibroblast cell clusters were seeded into collagen gels 
containing collagen type I with or without fibrinogen, with thrombin then added to initiate 
fibrin polymerization. Collagen gels with fibroblast spheroids led to modest contraction of the 
original gel compared to that of gels containing fibroblasts as single cells. Collagen gels 
containing only 7% fibrin reduced contraction significantly (II). 
 
Keratinocyte viability on rhCol-III was analyzed with gfp-HaCaT cells in co-culture 
setting with keratinocytes and CRL2088 fibroblasts physically separated by a porous 
membrane (IV). Fibroblasts stimulated gfp-HaCaT cell proliferation, which was inhibited 
with two EGF-receptor tyrosine kinase inhibitors; PD153035 and AG1478. When primary 
porcine keratinocytes were seeded on rhCol-III-coated wells, they adhered within 2 hours. 
However, under serum-deprived conditions fibroblast support was required for cell 
proliferation and migration (data not shown). 
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5.4 Partial thickness wound healing model (III) 
 
The effect of finectra on healing of dermal wounds was evaluated with a porcine 
partial-thickness wound-healing study (III). We compared epidermal resurfacing of treatment 
wounds was compared saline-treated controls and monolayer-treated controls. Finectra 
treatment resulted in a significantly greater change in epithelium amount than for either saline 
or monolayer-treated wounds. The biological effect of fibroblasts was also evident in 
monolayer controls. The effect, however, was significantly less (30%). The area of re-
epithelialization compared with that of saline-treated controls was 8.6 ± 6.6% larger in 
monolayer  and 41.1 ± 9.0% in finectra-treated wounds (Figure 8A). Re-epithelialization 
originated from lateral wound edges as well as from hair follicles in which the upregulation of 
K-14 and PCNA was evident. The NIRS camera provided data with a statistically significant 
negative correlation between the ECC of oxyhemoglobin (oHb) and epidermal/epithelial 
thickness (r = 0.63, p = 0.0013). However, no statistically significant difference appeared in 
the ECC of oHb or doHb between treatment groups. Average epithelial islet-area per wound 
section was significantly larger in finectra-treated wounds, and cell migration from the wound 
edges with a leading edge was significantly improved. Both finectra and monolayer treatment 
stimulated granulation tissue formation more than saline controls did (p < 0.001 and p <0.05, 
respectively). Finectra stimulus had, however, a significantly greater effect as compared to the 
monolayer controls (p <0.05). 
 
5.5 Full thickness wound healing and cell transplantation (IV) 
 
A porcine full-thickness wound experiment characterized the biocompatibility of 
rhCol-III as a dermal substitute and cell carrier. Primary porcine keratinocytes and fibroblasts 
were isolated from a skin sample take from the animal week prior to surgery. Precultured 
keratinocytes and fibroblasts were centrifuged into separate layers of an rhCol-III matrix in a 
syringe. After overnight storage in +37°C, the bilayer gel was applied to 8-mm full thickness 
wounds and wounds were covered with a polyurethane dressing. On the fifth post-operative 
day, wound-healing was measured from H&E-stained sections with the same methods as in 
study III. Wound depth was significantly reduced in all treatments compared with depth in 
untreated controls, but no significant difference was observed between different treatment 
groups (data not shown). Wound contraction measured from digital images showed no 
difference between treatment groups. Granulation tissue thickness was significantly increased 
in all those treated compared with untreated controls, whereas no significant difference was 
observed with treatment groups measured both morphometrically and with imaging software. 
Transplanted pancytokeratin-positive keratinocytes were visible on the fifth postoperative day 
in the wound bed, indicating that rhCol-III could function as a carrier matrix for cells.  
 
Sirius Red staining was used to quantify total collagen amount. Polarized light 
microscopic images revealed that collagen arrangement was disorganized, and relatively little 
neocollagen had formed in the healing wound (IV). However, the amount of collagen was 
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increased most in wounds treated with either rhCol-III alone or with rhCol-III and 
keratinocytes. Fibroblast-containing gel was effectively removed from the wound whereas 
gels without cells or with only keratinocytes remained intact. As a conclusion, changing the 
cell-type composition of rhCol-III matrix from keratinocytes to a 50/50 fibroblast-
keratinocyte mixture dramatically altered the amount of collagen detectable by Sirius-Red 
staining in the wound (IV) (Figure 8B). This could be explained by the rhCol-III or 
keratinocyte-induced activation of collagen-degrading proteinases in the trasplanted 
fibroblasts. 
 
 
 
 
Figure 8A. Stimulation with conditioned medium from fibroblast aggregate cultures, finectra, increased 
amount of new epithelium in partial-thickness wounds compared with saline treated controls (*** 
p<0.001 as compared to monolayer controls) 
 
 
 
Figure 8B. Treatment of full-thickness wounds with autologous keratinocytes in an rhCol-III matrix 
increased amount collagen; fibroblast addition decreased detectable collagen (*** p<0.001). 
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6. Discussion 
 
Novel alternatives for treatment of skin defects have emerged from recent advances in 
the understanding of molecular mechanisms that regulate skin physiology and wound healing 
(Auger et al., 2009). These include identification of such potential therapeutic molecules as 
HGF. Together with the progress in material sciences, tissue-engineered active artificial skin 
substitutes mark yet another leap forward (review by Macri and Clark, 2009). Overall, the 
rationale for such regenerative wound treatments controllably providing growth factors and 
cytokines to the wound is to provide additional spatiotemporal cell stimuli to improve the 
complex coordination between tissue homeostasis and regeneration (Werner et al., 2007). In 
order for a regenerative wound treatment to be effective, the stimulating agent that is released 
must reach the wound bed in its active form at the right time. Moreover, its effect should be 
sufficiently sustained to enable biological functionality (Macri and Clark, 2009).  
 
Topically administered growth factor therapies have been under intensive study, 
Experience from clinical trials thus far have, however, clearly demonstrated that single-agent 
therapies such as administration of a single growth factor influence wound repair only to a 
mild to moderate degree. In hindsight, this should have been less unexpected because the 
elaborate wound repair process has considerable plasticity and several levels of control, and 
comprises a legion of active modulators (Gurtner et al., 2008). Thus, the synergic application 
of two or more carefully selected growth factors is, though as yet unexplored, a prospective 
alternative for skin wound treatment (Robson, 1997; Chen et al., 2010). The focus of this 
thesis was to characterize the role of those biological paracrine mediators that are released 
from mesenchymal cells such as fibroblasts or bone marrow stromal cells in wound healing. 
The three-dimensional aggregation step employed was to induce further growth factor and 
cytokine production (Bizik et al., 2004; Kankuri et al., 2005). Additionally, my aim was to 
characterize clinically applicable means for transporting these factors with or without cells to 
the wound bed in a scaffold. The hypothesis was that a mixture of factors produced by 
activated cells best mimics a biological paracrine pattern of stimuli able to improve wound 
healing. 
 
6.1 Methodology 
6.1.1 Animal models 
 
Partial- and full-thickness wounds of young, healthy domestic pigs served as models 
for acute wound healing in the animal experiments (III-IV). The porcine partial-thickness 
wound model has several advantages. Porcine skin is superior to rodent skin in its anatomical 
and physiological similarity to human skin. Additionally, the structure of the epidermis is 
similar, and since adnexal structures participate actively in healing in both humans and pigs, 
the model is considered a good one for epithelial healing. Thus, the structural reconstruction 
and healing response can be considered relevant also in response to a human growth factor 
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stimulus. The pigs, however, have a powerful innate healing capacity that presents a challenge 
for improving and measuring wound healing. Possibilities to artificially slow the innate 
healing response by chemical means include streptozocin. Because these models are also not 
without problems (such as increased mortality) (Marshall, 1979), we chose to use healthy pigs 
to enable characterization of any true responses. Anatomical variation in the dermal depth of 
porcine skin has an effect on wound healing. Because this observable in our experiments (III), 
we decided to evaluate the wounds as case-controls. 
 
6.1.2 Fibroblast and BMSC aggregate-derived factors and keratinocyte wound healing 
 
We observed that patient-derived BMSCs responded to cell clustering by induction of 
COX-2 and production of HGF (I). Reports on cell aggregation-activated fibroblasts and on 
fibroblast nemosis indicate that the central cytokines produced after 96 h of cell clustering are 
IL-6, IL-8, and HGF (Kankuri et al., 2008). HGF production was induced rapidly on both 
protein and mRNA levels after dermal fibroblast cell clustering (Kankuri et al., 2005). In 
addition, we showed that activated fibroblasts also release a principal keratinocyte stimulatory 
growth factor, amphiregulin (II). Both HGF and amphiregulin have explicitly been linked to 
keratinocyte migration and epithelialization in wound healing (Toyoda et al., 1995; 
Schelfhout et al., 2002). Moreover, Toyoda et al (2001) report that overexpression of HGF 
increases vascularization and granulation tissue formation in vivo, indicating that it plays 
multiple roles in wound healing. Research done by Räsänen et al (2010) suggested that 
HaCaT-keratinocytes respond to fibroblast nemosis by increased migration in both a 
chemotactic and a fibronectin-mediated manner. Furhermore, they reported that TGF-β1 
induced upregulation of COX-2 in migrative keratinocytes. 
 
Upregulation of COX-2 and an imminent inflammatory response has been linked to 
clustering of dermal fibroblasts (Bizik et al., 2004). The induction of COX-2 was followed by 
production of prostaglandins (PG), notably PGI2, PGE2, and PGF2α (Bizik et al., 2004). PGs, 
studied extensively, are principally considered to be proinflammatory mediators. In skin 
physiology, PGE2 plays a role in hair follicle development and hair growth, and expression of 
the PGE2 receptors EP3 and EP4 alter during the hair-growth cycle in mice (Torii et al., 2002; 
Lee et al., 2003). Due to observations that COX-2 is rapidly upregulated in acute wounds and 
that COX-2 inhibitors delay early epithelialization, it is clear that PGs also play a central role 
in wound healing (Futagami et al., 2002; Lee et al., 2003). Kaneko et al (1995) reported PGI1 
analogues to inhibit keratinocyte cell growth in vitro whereas PGE1 has the opposite effect. 
Interestingly, in the same study the authors concluded that conditioned medium collected 
from fibroblasts activated by PGI1 contained elevated amounts of IL-6, and it enhanced 
keratinocyte migration. Correspondingly, in our studies a PGI2 analogue, 6α-PGI1, used to 
stimulate keratinocyte migration, displayed no such effect (I). 
 
As mentioned, both IL-6 and IL-8 act as mitogens and also promote keratinocyte 
chemotaxis because it is crucial for wound healing (Schröder, 1992; Gallucci et al., 2004). 
Grimstadt et al (2011) reported recently that in acute-wound fluid collected from reduction 
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mammoplasty wounds, the most abundant cytokines found were IL-6 and IL-8. This 
confirmed findings regarding the cytokines present in fluid of acute wounds. Interestingly, a 
recent findings was a that conditioned medium from MSC cultures supports keratinocyte and 
fibroblast migration in vitro and the main paracrine components are IL-6 and IL-8 (Walter et 
al., 2010).  
 
HGF-induced keratinocyte migration 
 
We showed that BMSCs spheroids induced keratinocyte migration utilizing, HGF and 
c-Met. Stimulation with conditioned medium caused rapid autophosphorylation of hepatocyte 
growth factor receptor (HGFR): c-Met (at the tyrosine residues Y1234/Y1235), an effect 
inhibitable by SU11274. The receptor phosphorylation thus indicated that HGF is one on the 
main factors contributing to the nemosis-induced keratinocyte responses. BMSC-conditioned 
medium supported keratinocyte migration, which was inhibited to a lesser extent by an anti-
HGF antibody. It thus remained unclear, whether HGF is the sole factor contributing to 
keratinocyte migration. Additionally we know that EGFR and PG-receptors have crosstalk 
with c-Met. An autocrine, transcription-dependent EGFR activation after HGF stimulation has 
been reported, and c-Met is able to dimerize or interact with several partners on the cell 
membrane (Han et al., 2006).  
 
6.2 Results 
 
6.2.1 Partial-thickness wound-healing with fibrin-trapped growth factors from aggregate 
cultures 
 
Porcine partial-thickness wounds treated with conditioned medium from cell aggregate 
cultures or from standard monolayer cultures revealed improved granulation tissue formation 
and epithelialization. However, aggregate-conditioned medium treatment was statistically 
significantly better (III). Studies made of partial thickness model have revealed that single 
growth factors indeed exert a favorable effect on epithelialization. Breuing et al (1997) 
reported improved re-epithelialization with topical 100 ng/ml EGF within 4-5 days,  as 
measured by protein flux through the wound surface. Analogously, a study using the porcine 
partial thickness wound showed that topical 1μg/ml EGF treatment almost halved the time 
needed for epithelialization (Hong et al., 2006).  
 
Nevertheless, there is limited number of reports on the use of multiple growth factors 
in porcine wound healing. Danilenko et al (1995) showed that a synergic effect of PDGF and 
KGF can enhance granulation tissue formation in a porcine burn wound model, but with no 
effect on epithelialization. Moreover, a clinical study by Robson et al (2000) evaluated the 
combined effect of GM-CSF with bFGF in the treatment of pressure ulcers with unsuccessful 
results. Reports also concern platelet lysate, a mixture of various growth factors released from 
activated platelets; Henderson et al (2003) reported that in a porcine superficial burn model, 
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autologous platelet gel (a concentration of platelet-lysate) stimulated collagen- and 
granulation-tissue formation with fibroblast proliferation, but re-epithelialization was not 
enhanced. Vermeulen et al (2008) later described combining PRP with a fibrin matrix and 
keratinocytes to enhance re-epithelialization in a porcine full-thickness model. On the other 
hand, the conclusion of one randomized clinical trial on the platelet-rich fibrin was that 
healing of neither donor sites nor autografts was significantly improved (Daniselsen et al., 
2008). It is possible that donor-dependent variations of the PRP-product make comparison 
between different studies difficult. 
 
 
Figure 9. Conclusion of results: paracrine stimulatory factors from cell aggregate cultures stimulate 
keratinocyte viabilitysand migration when combined with biomatrices such as fibrin and collagen 
6.2.2 Full-thickness wound treatment with keratinocyte- and fibroblast-populated recombinant 
human collagen III matrix 
 
Recombinant materials provide a safer alternative for animal-derived collagens but the 
biocompatibility of recombinant collagens is still unclear. We sought to characterize the use 
of a recombinant human collagen carrier for autologous keratinocyte and fibroblast 
transplantation to full-thickness wounds (IV). Results showed keratinocyte transplantation 
with rhCol-III was successful and that addition of fibroblasts into the keratinocyte transplant 
dramatically altered the amount of detectable collagen in the wound. This ECM degrading 
effect could be caused by activation of fibroblast by either the collagen matrix or 
keratinocytes. This information must be taken into account in the future when designing 
recombinant collagen hydrogels. 
 
6.2.3 Future prospects 
 
Even though the clinician's repertoire includes a variety of treatments targeted at complex 
skin wounds, many of the present tissue-engineered products still contain foreign material, 
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often of xeno- or allograft origin. Viral vector transfection and gene modification can serve in 
production of growth factors in situ, but bear risks for viral infection and oncogenesis, thus 
being an unsafe therapy option (Anson, 2004). Importantly in our approach, no other added 
factors besides those produced by normal human cells are present. Further characterization of 
the conditioned medium from mesenchymal cells closely linked to promotion of wound 
healing may in future contribute to identification and design of the most beneficial 
combination of novel wound healing therapeutics.  
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7. Summary and conclusions 

The purpose of this study was to investigate the effect of paracrine mediators from 
aggregation-activated or non-activated dermal fibroblasts and bone marrow stromal cells on 
critical aspects of wound healing: keratinocyte migration, epithelialization, and granulation-
tissue formation in experimental in vitro and in vivo wound models. Furthermore, we aimed 
to characterize means of improving growth factor transport and keratinocyte transplantation 
utilizing the biological matrixes fibrin and collagen. The findings and conclusions are the 
following: 
 
I Keratinocytes respond to nemosis-induced stimulatory factors in a wound healing 
model. Cell aggregation of patient-derived bone marrow stromal cells elicits 
upregulation of COX-2 and HGF and induces keratinocyte migration in model 
keratinocytes, HaCaT cells. The paracrine mediators stimulate keratinocytes by 
utilizing the c-Met/PI3K /MEK 1/2/ ERK 1/2-pathway. 
 
II The HGF and amphiregulin-containing conditioned medium from dermal fibroblast 
aggregate-cultures enhances fibrin matrix cell-transplantation properties by leading to 
increased primary human keratinocyte migration and viability. 
 
III Conditioned medium from dermal fibroblast-aggregate cultures improves wound 
healing by promoting epithelialization and granulation tissue formation in three days, 
when applied topically to the wound bed in an in vivo porcine partial thickness wound 
model. 
 
IV Recombinant human collagen type III supports keratinocyte transplantion and 
improves healing of in vivo full-thickness wounds by increasing granulation tissue 
formation and collagen content in a porcine wound model. Keratinocyte viability and 
proliferation on recombinant human collagen type III is enhanced by fibroblasts via 
EGF stimulation. 
 
In conclusion, when fibroblasts and bone marrow stromal cells are cultured as cell 
aggregates, the biological activation initiated results in release of paracrine factors including 
HGF and amphiregulin; this improves skin wound healing. This novel method of production 
of healing-inducing factors has a therapeutic potential for treatment of complex skin wounds. 
Futhermore, with tissue engineering, these factors can be combined to biomaterials to 
stimulate guided tissue regeneration in the damaged skin. 
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